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ABSTRACT

AUGMENTATION OF RAS-INDUCED CELL TRANSFORMATION:
A NEW ROLE FOR MIR-200A IN MALIGNANCY
Lindsey Erin Becker
April 2, 2014

Cancer is a multistep disease that begins with malignant cell transformation and
frequently culminates in metastasis and death. MicroRNAs (miRNAs) are small
regulatory 21-25-nt RNA molecules and are frequently deregulated in cancer. The
majority of miRNAs are estimated to be co-expressed with neighboring miRNAs as
clusters. Many miRNA clusters coordinately regulate multiple members of cellular
signaling pathways or protein interaction networks. miR-200a is a member of the miR200 family, which are known to be strong inhibitors of the epithelial to mesenchymal
transition. As such, the tumor suppressive role of miR-200a in oncogenesis has been well
studied; however, recent studies have found a proliferative role for this miRNA as well as
a pro-metastatic role in the later steps of cancer progression. In this study, we employed a
biphasic approach to determine miRNA involvement in malignant cell transformation.
First, we screened 366 human miRNA minigenes to determine their effects on the four
major cancer signaling pathways culminating in AP-1, NF-κB, c-Myc, or p53
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transcriptional activity. The second phase of this study was an epithelial cell screening
assay to determine the ability of miRNAs to transform epithelial cells. In our miRNA
cluster profiling study, we found that miR-200a down-regulates p53 activity. miR-200a
was demonstrated to directly target p53, reduce protein levels, and inhibit apoptosis. We
also found that miR-200a enhances Ras-mediated transformation of MCF10A cells.
Furthermore, miR-200a transforms MCF10A cells and induces tumorigenesis in
immunocompromised mice by cooperating with a Ras mutant that activates the RalGEF
effector pathway. These results demonstrate a role for miR-200a in malignant
transformation and reveal a specific cellular environment in which miR-200a acts as an
oncomiR rather than a tumor suppressor by cooperating with oncogene activation in the
classical two hit model of cell transformation.
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CHAPTER I
INTRODUCTION: CANCER AND MICRORNAS
Cancer Statistics and Cancer Progression
One in three Americans will be diagnosed with cancer in his or her lifetime. In
2013, an estimated 1.6 million new cases of cancer were diagnosed, and over half a
million Americans died of cancer. It is the number two leading cause of death in the
United States, accounting for nearly one in every four deaths. The most frequently
occurring cancers in men are prostate, lung, and bladder. In women, the most frequently
occurring cancers are those arising in the breast, digestive system, and respiratory system.
In both men and women combined, lung cancer was responsible for 159,480 deaths in
2013, over a third of all cancer related deaths. The second most deadly cancers in men
and women are prostate and breast, respectively. Colon cancer claims the third most
lives for both sexes. Despite these grim numbers, cancer death rates are declining in both
sexes [1]. In 2009 alone, 152,900 cancer related deaths were avoided, thanks in part to
advances in treatment efficacy. Even more important, however, are advances in detecting
and diagnosing cancer at early, more treatable stages [2,3].
There are multiple forms of cancer, classified by the cell type from which they
arise. The five most common types of cancer—breast, prostate, lung, colon, and
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bladder—are examples of carcinomas, or cancers arising from epithelial cells.
Carcinomas are the most common form of cancer.
Cancer is comprised of a progressive series of steps, beginning with malignant
cell transformation, which leads to primary tumor formation. Vascularization of the
tumor occurs to allow survival and growth. Tumor cells become invasive and motile by
undergoing an epithelial to mesenchymal transition (EMT). During this process,
epithelial cells, once constrained by the necessity of cell:cell and cell:basement
membrane contacts for survival, experience changes in gene expression that result in an
elongated, mesenchymal phenotype and the ability to migrate and invade local stroma
[4]. This mobile, mesenchymal phenotype also allows for subsequent intravasation of
invasive cancer cells into the blood stream, allowing them to circulate throughout the
body. Circulating cancer cells will then extravasate from the blood stream to colonize
new sites on distal tissues. New studies have shown the importance of the reversal of
EMT, the mesenchymal to epithelial transition (MET), in metastatic colonization at distal
sites [5-7]. By developing a more stable epithelial phenotype, cells that were once
mobile and invasive acquire the characteristics necessary for formation of a secondary
metastatic tumor. It is rarely the primary tumor that is responsible for cancer mortalities,
but rather the late stage metastatic disease that accounts for over 90% of cancer related
deaths [8-10]. The study of the very first step of cancer progression—cell
transformation—is thus crucial to provide the means for diagnosing and treating cancer
before progression to the deadly metastatic stage.
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Malignant Cell Transformation
Malignant cell transformation occurs when a normal somatic cell develops the
ability to proliferate indefinitely and escape the cell cycle control checkpoints and
apoptotic signaling that normally eliminate cells with hyper-activated proliferative
signaling pathways [11]. Cells that acquire this unrestrained proliferation phenotype in
vivo can develop into a tumor. In 2000, Robert Weinberg elegantly described the
Hallmarks of Cancer, identifying the six abilities acquired by cancer cells that allow them
to form tumors, induce angiogenesis, and metastasize [12]. Four of these six hallmarks
pertain specifically to cell transformation: sustaining proliferative signaling, resisting
cell death, evading growth suppressors, and enabling replicative immortality. More
recently, Weinberg updated these hallmarks to include four new emerging hallmarks of
cancer: dysregulating cellular energetics, avoiding immune destruction, genome
instability and mutation, and tumor-promoting inflammation. Genome instability and
mutation influences the genetic changes that induce malignant cell transformation, and so
they will be discussed within the context of the four hallmarks of transformation.
Sustaining Proliferative Signaling
Normal somatic cells receive external and internal signals throughout their normal
lifespans that regulate proliferation. During development, mitogenic stimuli signal
differentiated cells to proliferate into a specified organ, and then proliferation ceases.
Under normal conditions, homeostasis of the cells, and thus the organ itself is maintained
via cell:cell signals, cell:basement membrane signals, as well as various paracrine and
endocrine signals in the entire organism. While much of the homeostatic cell:cell
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signaling under normal conditions is not completely understood, proliferative signals in
cancer progression are well studied. The crux of the hallmark of sustaining proliferative
signaling relies on the propagation of cell signaling pathways that result in proliferation
despite a lack of actual proliferative stimuli.
Activation of mitogenic downstream signaling pathways; a focus on Ras
Unrestrained proliferation can occur through multiple mechanisms; however, a
common feature of hyper-proliferative cancer cells is the activation of downstream
components of mitogenic signaling pathways. A potent example is the classical
oncogene, Ras. Ras is the most frequently mutated gene in pancreatic cancer and its
associated preneoplastic lesions; it is known to stimulate cell proliferation and contribute
to the induction of pancreatic cancer [13].
Ras activation occurs in response to growth factor signaling. Growth factors bind
receptor tyrosine kinases, which become activated and recruit the guanine nucleotide
exchange factor, SOS, to the plasma membrane where it facilitates the exchange of Rasbound GDP to GTP [14-16]. Binding of GTP induces a conformational change in Ras to
its active state, allowing it to bind its potent downstream effectors at the plasma
membrane where they are then activated. The three main effectors in the Ras signaling
pathway are PI3K, RalGEF, and Raf [17-19]. Stimulation of these pathways activates
Akt signaling, Jnk/AP-1 transcriptional activity, and the MAP kinase cascade,
respectively. Ras-mediated activation of multiple cell signaling pathways is tightly
regulated by GTPase activating protein, which stimulates the inherent GTPase activity of
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Ras shortly after Ras becomes activated. The resulting hydrolysis of GTP to GDP returns
Ras to its inactive form, shutting off the signaling cascade [17,20].
Normal human Ras is a protooncogene, which is a broad class of genes that
control growth or proliferation and, if dysregulated, can cause cancer. The most well
studied mutation of Ras is a G12V mutation where glycine 12 is mutated to valine [21].
This amino acid change ablates the GTPase activity of Ras, regardless of the presence of
GTPase activating protein. Loss of GTPase activity causes constitutive Ras activation,
and thus continual stimulation of downstream proliferative signaling pathways, thereby
effectuating its conversion from protooncogene to full-fledged oncogene.
In addition to mutations in Ras itself, components of its downstream effector
pathways may also be mutated to lead to excessively high levels of proliferative
signaling. Amplification of Akt has been documented in pancreatic, colon, breast,
endometrial, and ovarian cancers [22]. Akt has a wide variety of targets that it
phosphorylates including Mdm2, an inhibitor of p53; Raf, an upstream component of
Map kinase signaling; and mTOR, a signaling protein responsible for angiogenesis as
well as upregulation of cell cycle progression genes like c-Myc [23-26]. Akt can also
phosphorylate targets to inhibit their activity, for example, Caspase-9, an apoptotic
effector protein, and p21, an inhibitor of cell cycle progression [27,28]. The crucial
element of the oncogenic activity resulting from activating mutations in, or amplification
of, genes like Ras and Akt is the lack of dependence on growth factor signaling to induce
activity. In other words, the cell continually propagates signals to proliferate despite a
lack of normal upstream proliferative stimuli.
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Disruption of proliferation-regulating pathways
In addition to over-activation of proliferative signaling, e.g. the activating G12V
Ras mutation or amplification of Akt described above, loss-of-function of regulatory
members of proliferative signaling pathways can lead to sustained proliferative signaling
and induction of cancer. These regulatory proteins are generally known as tumor
suppressors due to their role in inhibiting cellular processes that, if left unchecked, can
induce malignant cell transformation or contribute to cancer progression. The tumor
suppressor Phosphatase and Tensin Homolog (Pten) is a potent regulator of the PI3K/Akt
activation pathway. PI3K signaling is stimulated when Ras is activated [29]. After being
recruited to the plasma membrane, it phosphorylates Phosphatidylinositol 4,5bisphosphate (PIP2) to form phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3
serves as a docking site for Phosphoinositide-dependent Kinase 1 (PDK1) which
phosphorylates Akt on threonine 308 to serve as its initial activation step [30]. Pten is a
phosphatase that dephosphorylates PIP3 to PIP2, blocking the recruitment of PDK1 to the
plasma membrane and ultimately inhibiting the activation of Akt. Pten mutations and
loss of heterozygosity have been found in brain, prostate, breast, ovarian and pancreatic
cancers [22]. Loss of this kind of regulatory mechanism also allows for inappropriate
proliferative signaling.
Senescence
A natural barrier to malignant cell transformation is oncogene-induced
senescence. Senescent cells are characterized by lack of proliferation, lack of response to
growth factors, and an enlarged, flattened morphology. Induction of this phenotype can
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occur in response to direct DNA damage or in response to oncogene activation [31].
Cells with activated oncogenes stimulate proliferative downstream signaling that induces
DNA replication at inappropriately high levels, which triggers a DNA damage response
that signals the cell to undergo senescence [32]. When Ras is constitutively activated in
cancer, its effector, Raf, initiates the Map kinase signaling cascade. Map kinase signaling
is potently mitogenic, and is particularly responsible for inappropriately high levels of
DNA replication [33-35]. The prodigious number of replication forks during oncogeneinduced hyper-replication induces a DNA damage response through the ATM pathway,
which ultimately up-regulates p53 activity [32,36]. The transcriptional target of p53,
p21WAF1/CIP1, is induced when p53 levels are increased in response to DNA damage, and
it inhibits the activity of Cyclin-Dependent Kinases (CDKs) which phosphorylate
Retinoblastoma protein (Rb). Phosphorylated Rb sequesters the transcription factor E2F,
blocking its ability to promote progression through the cell cycle from G1 to S phase
[37]. Other cell cycle arresting pathways converge, and ultimately, if the cell fails to
repair the damage that initially induced the DNA damage response, the cell will
permanently withdraw from the cell cycle and become senescent [37,38].
Senescence induction as a means of protection from oncogene activation is a first
line of defense against allowing malignant cell transformation to occur, but it is also a
dynamic process that continues throughout tumor formation [39]. By working to prevent
the consecutive steps of cancer progression that lead to metastasis and death, senescence
within existing tumors can continue to protect against more severely damaging effects of
cancer [8,40].
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Resisting Cell Death
Organized cell death, or apoptosis, is the process by which a cell systematically
disassembles itself to be digested by surrounding cells and specialized phagocytes. It is
characterized by chromatin condensation and membrane blebbing, and is carried out by
Caspase proteins. Caspases are thiol proteases that are present in the cell as inactive procaspases that are autolytically cleaved to form their active Caspase form in response to
apoptotic signaling. Once active, these proteases cleave structural proteins and other
important cell components. Apoptosis is necessary during normal development to
eliminate extraneous cells. For example, the cells between a developing mammal’s
phalanges undergo apoptosis to allow for formation of individual digits. Apoptosis is
also important for the elimination of cells that pose a threat to the organism, e.g. cells
with the potential to become cancerous. Cells of this nature are typically cells that have
excessive levels of DNA damage or mutations that either activate proto-oncogenes or
down-regulate tumor suppressors.
Apoptosis
Apoptosis is exacted through two pathways: an intrinsic or mitochondrial pathway
and an extrinsic pathway induced by death ligands binding to cell surface receptors. Both
pathways ultimately result in the activation of effector Caspases, which are thiol
proteases that cleave after aspartic acid residues. These apoptotic-specific proteases
cleave structural proteins, signal transducers, regulators of transcription, repair factors,
and many other targets within the cell. The apoptotic cell also prepares itself for
phagocytosis by actively flipping phospholipids, specifically phosphatidyl serine, from

8

the inner to the outer leaflet of the cell membrane, creating a signal for phagocytosis of
the disassembled cell by macrophages [41].
Genes upregulated by p53 in response to DNA damage include Puma and Noxa.
These proteins are pro-apoptotic BH3 domain-containing Bcl-2 family members that
exert their effects by antagonistically binding anti-apoptotic Bcl-2 family members,
causing the release of BH123 family members such as Bax, another p53 transcriptional
target. Release of Bax allows for its oligomierization and translocation to the
mitochondrial outer membrane, where it causes permeabilization of the outer membrane
and release of Cytochrome C. Cytochrome C is an important second messenger that
binds and activates the adapter protein Apaf-1. Apaf-1 binds procaspase 9 and forms
aggregates, allowing for autolytic cleavage to the active form of Caspase 9. Activation of
Caspase 9 triggers a Caspase cascade that leads to activation of more Caspase proteins,
which can then begin degrading structural proteins to prepare the cell for phagocytosis.
This tightly regulated mechanism of cell death is necessary for maintenance of healthy
tissue, and loss of this crucial process contributes to cell transformation and the
persistence of cells with dangerous mutations.
Cancer cells frequently harbor dysregulated apoptotic machinery. An example is
the translocation of anti-apoptotic Bcl-2 to an immunoglobulin locus causing
upregulation of Bcl-2 expression, and promotion of cell survival in follicular lymphoma
[42]. In addition, p53 is mutated in nearly half of all cancers [43,44], and its loss of
function contributes to the survival of cancer cells.
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DNA Damage Response
DNA damage is caused by endogenous and exogenous insults to the cell.
Endogenous causes of DNA damage include reactive oxygen species and replication fork
collapse. Exogenous sources of DNA damage range from radiation i.e. UV light, to
chemical mutagens, to viruses. DNA damage includes the formation or addition of bulky
adducts such as the thymidine dimers caused by excessive UV light and breakage of
DNA strands [45]. The most deleterious form of this is the double stranded break (DSB)
[46].
When a cell acquires DNA damage, several mechanisms are activated to allow for
repair. The first signal relayed is that of the presence of DNA damage such as a DSB. In
response to this form of damage, normally supercoiled DNA relaxes [45]. This change in
chromatin structure initiates the recruitment of Poly-ADP-ribose Polymerase (PARP)
proteins and binding of kinases such as Ataxia-Telangiectasia Mutated (ATM) and DNAPK to the break site in order to modify histones. Histone modifications include covalent
linkage of Poly-ADP-ribose (PAR) chains by PARP proteins and phosphorylation of
lysines by ATM and DNA-dependent protein kinase (DNA-PK). The presence of PAR
chains stops replication and transcription in the area of the DSB, and phosphorylated
histones recruit DNA damage response proteins such as p53 and BRCA1 [47]. BRCA1
is a well-studied tumor suppressor, recognized largely for its mutation in familial breast
cancer [48]. The transcription factor and tumor suppressor p53 has long been known as
the guardian of the genome. Its functions are well studied and include transcriptional
upregulation of proapoptotic genes [49]. p53 is maintained at low basal levels in the cell
by its inhibitory protein, Mdm2, which inhibits p53 function by acting as an ubiquitin
10

ligase to target p53 for proteasomal degradation as well as by binding to and blocking the
DNA binding domain of p53, inhibiting its activity as a transcription factor [50]. Upon
detection of DNA damage, DNA-PK and ATM bind the DSB and phosphorylate histone
H2AX [51]. This DSB-detection signal recruits p53, which is then phosphorylated on its
N-terminus at serine 15 by DNA-PK or ATM. Phosphorylation at this site blocks
inhibition by Mdm2 and promotes binding to p53 response elements in the promoter
regions of proapoptotic genes [41,52,53].
Other signal cascades involve activation of cell cycle check point proteins and
DNA repair enzymes to arrest the cell cycle to allow time for appropriate repair of
damaged DNA. Repair of DSBs can occur through two pathways: Homologous repair
(HR), and Non-homologous end joining (NHEJ). NHEJ frequently introduces errors, and
in the case of multiple DSBs, may lead to fusion of nonhomologous chromosomes. Once
the cell repairs a DSB, the checkpoint machinery is deactivated, and the cell is once again
allowed to progress through the cell cycle [54]. Newly introduced errors that were not
corrected become mutations that can have deleterious effects such as deactivation of
tumor suppressors like p53 and other pro-apoptotic genes, up-regulation of oncogenes,
and other gross changes to the cell’s morphology and metabolism.
Oncogene Activation
Propagation of genetic errors such as point mutations, gene amplifications, and
chromosomal translocations can lead to disruptions in gene expression and/or gene
function. A potent example is the proto-oncogene Myc, which is the most frequently
amplified oncogene in human cancers and whose translocation was first discovered as the
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driving force in Burkitt Lymphoma [55-57]. Myc is a tightly regulated transcription
factor whose target genes include ODC and Gadd45α, both of which are implicated in cMyc driven proliferation [58]. Low levels of Myc activity are tolerated in the cell and act
as a signal to grow and proliferate; however, high levels of Myc activity trigger activity
of Arf, a tumor suppressor that induces cell cycle arrest via p53 and can ultimately lead to
apoptosis [59,60]. In this way, the strongly oncogenic signaling of Myc is quelled before
out of control proliferation occurs. Other proto-oncogenes also induce apoptosis as a
safety mechanism if their signaling or activity becomes abnormally high.
Overall, loss of the apoptotic response allows cells to acquire and propagate
mutations that would normally induce the DNA damage response pathway and lead to
apoptosis. Propagated mutations that activate oncogenes result in unrestrained
proliferation or growth, which are normally controlled by feedback mechanisms that
detect such inappropriate signaling levels and induce apoptosis. Loss of apoptotic
pathway components then results in unimpeded cell survival.
Evading Growth Suppressors
As established earlier, malignant cell transformation depends on loss of tumor
suppressors that induce apoptosis, arrest the cell cycle, or regulate proliferative signaling.
These include p53, Rb, and Pten, respectively, demonstrating the significant overlap of
Weinberg’s Hallmarks of Cancer within the malignant cell transformation. Impediments
to unrestricted cell survival and proliferation are frequently lost or mutated in cancer, and
their mechanisms are well studied; however, more intricate processes of cell growth
suppression exist including contact inhibition and differentiation.
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Contact Inhibition
Non-transformed cells, when grown in culture, will experience a slowing of
proliferation as they reach confluence. This phenomenon was first discovered in the
1960s when cells were first being experimentally cultured in laboratories, and was termed
the Hayflick phenomenon. It has recently been studied more extensively, however it is
not completely understood, and its relevance in vivo is not completely established [31].
What has been deduced is that cells, particularly epithelial cells, experience growth
inhibition with respect to adjacent cells. The cell signaling pathways responsible for this
are not fully known, but it has been shown under various conditions and with multiple
cell types that non-transformed cells will grow into a single-layered sheet of cells in vitro,
mimicking the single epithelial layer seen in vivo such as in the intestinal wall or luminal
mammary gland ducts [12]. The physical touching of the cells relays signals, most likely
through cell:cell junctions and extracellular structural proteins, that inhibit proliferation.
A distinct feature of transformed cells is their ability to proliferate despite the growth
inhibitory signals being relayed by their contact with other cells. The result of avoiding
these particular growth suppressing signals is a mound of cells that are continuously
proliferating, or, in vivo, a tumor.
A second form of growth control occurs when cells lose cell:basement membrane
contacts. This specific form of apoptosis is called anoikis, and is responsible for the
organized cell death of cells that lose such crucial structural contacts [61]. A hallmark of
cancer cells is their ability to either escape the constraints of normal tissue structures, or
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to degrade and invade the basement membrane. This invasive and migratory ability is
coupled to the ability to evade the growth-suppressing signals that would induce anoikis
in response to loss of these structural contacts [62].
Enabling Replicative Immortality
Telomeres
Telomeres are protein-DNA complexes that protect the ends of linear
chromosomes from being targeted by DNA damage-repair machinery. They consist of a
double stranded (DS) stretch of tandem TTAGGG repeats that terminates in a single
stranded (SS) G-rich 3’ overhang. Telomere associated proteins such as the Shelterin
complex coat this SS region to prevent its recognition as DNA damage. Telomeric
proteins also aid in the formation of complex structures such as G-quadruplexes and Tloops that cap the end of the chromosome, further disguising the chromosome end from
being recognized as DNA damage [63]. Replication of telomeres is a complex and
important process. Coordinating the removal of this plethora of proteins with
dismantling the complex structures within the telomere is a finely tuned process that
serves to maintain the delicate balance between a healthy cell and a prematurely
senescing cell. Replication also poses a significant challenge to telomeres because with
each round of replication, DNA on the end of the chromosome is lost, due to the inability
of the replication machinery to replace RNA primers with DNA on the lagging strand.
Aberrant replication can lead to fork pausing and unreplicated telomeres which cause
premature senescence and cell death. Loss of telomere-associated proteins can lead to
severe physiological defects such as the premature aging seen in Werner syndrome. The
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leading strand of the telomere, however, does not experience this shortening due to
Okazaki fragmentation. Instead, DNA polymerase replicates off the end of the telomere,
leaving behind a blunt end in need of resectioning by an endonuclease to form the
classical 3’ overhang necessary for proper telomere function. Several reports suggest that
this nucleolytic activity is performed by Apollo, a nuclease found both at telomeres and
double stranded breaks (DSBs). The function of Apollo requires stimulation by the
multifunctional protein, Trf2.
Trf2 is a conserved telomeric protein with a wide repertoire of functions. It is a
member of the Shelterin complex that helps disguise the telomere from being recognized
as DNA damage, and it functions in the formation and stabilization of the t-loop that
buries the single stranded 3’ overhang within the double stranded portion of the telomere.
Trf2 also recruits Apollo [64], whose endonuclease activity is stimulated by Trf2 both to
relieve topological stress during replication [65] and to resection the blunt end of the
leading strand telomere into a 3’ overhang directly following replication [66,67].
Notably, Apollo’s interaction with Trf2 at this significant structure is necessary to
prevent major telomere dysfunction [67]. Trf2 has also been recently implicated by
various sources in the recognition and repair of DSBs in response to various forms of
damaging radiation [68-70]. Trf2 is rapidly phosphorylated in response to DSBs. This
phosphorylation has proved necessary for both the transient recruitment of Trf2 to these
DSBs and the initiation of DNA repair [70]. Interestingly, in times of telomere crisis, or
during the alternative lengthening of telomeres (ALT) pathway, phosphorylated Trf2 has
been shown to localize to the telomere [70]. This discovery is not unexpected because
many DNA damage-related proteins and telomeric proteins have been found to function
15

within both contexts [69,71,72]. Apollo is also recruited to DSBs and interacts with
ATM [73], a crucial signal transducer in the DNA damage recognition pathway that leads
to non-homologous end joining (NHEJ). Trf2 is proposed to hold ATM inactive at
telomeres and DSBs. Although controversial, it has been shown that ATM may mediate
phosphorylation of Trf2 in response to DNA damage [68,70,74].
The presence of the telomere protects important genomic DNA from this loss, but
overall, this shortening of telomeres is part of the aging of the cell and eventually results
in naturally occurring senescence. With each round of cell division, a cell must replicate
its DNA before separating into daughter cells. The DNA polymerase enzyme responsible
for replicating the genome is not able to fully replicate the ends of eukaryotic linear
chromosomes, and so with each round of cell division, small amounts of DNA remain unreplicated and are lost. The ends of chromosomes thus are comprised of several
kilobases of telomeric G-rich repetitive sequence. Cells are protected from the loss of
valuable genomic coding sequence DNA by telomeres because the repetitive telomeric
sequences do not contain genes, and telomere shortening during cell division serves as an
internal clock that senses when the telomeres have become too short for safe replication
and stops the cell from replicating. Because of the “internal clock” function of telomeres,
they are thought to play an integral role in the aging process. It is notable that the
proteins required for maintenance of the cell’s “internal clock” also function within the
DNA repair pathway, highlighting the complexity and overlap of Weinberg’s defined
hallmarks.
An enzyme complex called Telomerase is specifically required for synthesis of
telomeric sequence, and in normal cells, this enzyme is not fully expressed. Telomerase
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is comprised, minimally, of two subunits: TERT, a reverse transcriptase enzyme, and
TER, a large RNA subunit. A portion of TER contains the sequence specific template
utilized by TERT for adding nucleotides to uncapped telomeres. This sequence is small,
compared to the rest of the RNA strand, which is large, and whose sequence is largely
divergent between species. Phylogenetic studies have, however, determined the
conserved secondary structure of this RNA subunit, which has been determined to assist
in the protein interactions required for Telomerase holoenzyme recruitment to the
telomere, as well as further recruitment of other interacting proteins. In vitro, these two
subunits are all that are required for Telomerase reverse transcriptional activity; however,
in vivo, other interacting proteins, such as RNA binding proteins and DNA binding
proteins involved in recruitment and stabilization of the Telomerase:telomere interaction,
are necessary for the enzyme’s functionality. Telomerase is, in general, not active or
expressed in adult somatic cells; however, certain cell types such as highly proliferative
germ line cells, smooth muscle cells, and certain lymphocytes, retain Telomerase
functionality. In these cells, Telomerase activity and telomere length are maintained by a
phenotypic switch between capped and uncapped states of the telomere. As telomeres are
replicated, they become progressively shorter; however, telomere binding proteins such
as Apollo, Trf2, and other members of the Shelterin complex vivaciously coat the
telomere and help induce the secondary structures that telomeres form, e.g. T-loops. The
coating action of telomere-associated proteins complements the telomeric DNA
secondary structures, forming a protective cap on the chromosome’s end. This cap
prevents recognition of the DNA ends as DSBs, but also regulates Telomerase activity.
Capped chromosomes are less likely to be extended by Telomerase, however, as
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replicating cells’ telomeres are progressively shortened, they are less likely, and less able
to form protective caps, allowing for extension by Telomerase. By switching between
two forms—capped and uncapped—telomeres are maintained within upper and lower
length limits in Telomerase-positive cells. This regulation is crucial to avoid hyperextension of telomeres as well as recognition of telomeres as DSBs, both of which are
implicated in cancer.
Studies have shown that Telomerase is frequently reactivated in human cancer by
various mechanisms. Some reports show that Myc hyper-activation can induce TERT
expression, and it is one of the genetic changes found necessary by Weinberg’s lab for
oncogene cooperation-induced malignant cell transformation of human cells. Another
important mechanism of Telomerase reactivation in cancer cells is the re-activation of a
telomere maintenance program in order to bypass telomere damage-induced crisis and
senescence. Rapidly dividing cells frequently incur DNA damage due to the plethora of
replication forks that overwhelm the cell. Even more problematic during replication is
the process of dismantling the precarious secondary structures and intricate protein-DNA
complexes that cap the ends of the chromosomes. This process can pose problems during
normal replication, but during the rapid proliferation seen in cancer, this invariably leads
to damaged chromosomes. These telomere damage-induced foci (TIF) trigger a p53 and
Rb dependent DNA damage response, but the massive influx of DNA damage typically
overwhelms the cell and induces crisis. Crisis is comprised of misguided attempts by the
DNA repair machinery to repair the linear ends of chromosomes, having recognized them
as DSB. The end result is more damage as telomeres become fused and chromosomes
break. This cycle overwhelms the cell and eventually causes senescence. In the absence
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of p53 activity or intact DNA damage response pathways, or perhaps even due to the loss
of such pathways during crisis, a cell will survive crisis and propagate its gross genetic
damage as mutations. A crucial component of this is the re-activation of telomere
maintenance machinery. This almost always involves the re-expression of TERT. The
mechanisms of Telomerase reactivation are not fully known, but promoter mutations
have been found in many cancers, including thyroid, central nervous system and skin
cancers, glioblastoma, and over half of bladder cancers [75]. By establishing a telomere
maintenance program, the cell is able to avoid normal cellular lifespan limits, i.e. achieve
immortality. Immortality is one of the first steps in malignant cell transformation, and
expressing Telomerase is crucial in this immortalization process. However, primary
mouse embryonic fibroblasts MEFs, which express Telomerase, will not grow
indefinitely in culture; p53KO MEFs will, indicating that while Telomerase function is
involved in malignant cell transformation, it is a component of a complex, dastardly
process. It is notable that rodents constitutively express Telomerase, making their cells
easier to indefinitely culture in vitro, but presenting a major difference when studying
malignant cell transformation in rodent models.
Oncogene Cooperation
Weinberg’s hallmarks of cancer indicate the multiple processes that occur in
cancer, or, with respect to the specific four described above, malignant cell
transformation. In molecular biology terms, the requirement of multiple processes to
induce cell transformation translates to changes in cell signaling pathways, either by upregulation of proto-oncogene activity, or loss of either function or expression of tumor
suppressors. Although certain proteins, for example Ras, can activate multiple
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downstream effector pathways, multiple genetic changes are required for cell
transformation.
Historically this was attributed to viral oncogenes that stimulated Telomerase
activity, inhibited apoptotic and senescence-inducing machinery, and stimulated
proliferation [76-78]. However, Weinberg’s landmark paper in 1983 demonstrated the
requirement of two oncogenic hits to transform primary fibroblasts, and in so doing,
described for the first time the synergistic effect of Ras and Myc signaling to induce cell
proliferation without triggering apoptosis or senescence, which occurs when each
oncogene is over-expressed individually [79]. Cooperation of Ras and Myc coselects for
loss of p53 function. Dysregulation of Ras and c-Myc signaling delineates a classical
paradigm of oncogene cooperation, and continued activation of both of these pathways
allows cells to bypass senescence, escape apoptosis, and enter into a malignant,
hyperproliferative state [79,80].
In 2005, Boehm et al. delineated the nonviral genes necessary for human cell
transformation [81]. While Ras and c-Myc transform primary rodent cells, which express
Telomerase, human cells maintain more stringent checkpoints and require reactivation of
Telomerase, as well as loss of function of tumor suppressors. The specific changes in
human cellular pathways originally identified are activation of Ras, Myc, and TERT,
along with the loss of function of p53, Retinoblastoma protein, and PTEN [81]. All of
these combine to allow replicative immortality, hyperproliferation, and deactivation of
cell cycle checkpoints that would not under normal circumstances allow propagation of
genetic mutations that drive cell transformation [81-83]. The specific mutations
necessary to transform human cells is more complicated than in rodent cells, but the
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ultimate result for both is the survival of cells that are no longer governed by pathways
that regulate survival and proliferation. Such unrestrained cells are then able to form a
tumor.
MicroRNAs
History
MicroRNAs (miRNAs) are an abundant class of regulatory noncoding RNAs that
regulate thousands of genes across a vast array of signaling networks and cellular
functions [84]. The first miRNAs discovered were lin-4 and let-7 in C. Elegans [85,86].
These miRNAs were found to be expressed temporally and play crucial roles in
development. The field expanded to the cornucopia of small regulatory RNAs that it is
today with over 2500 mature miRNAs identified in humans alone. As research
progresses, it has become clear that miRNAs are key regulators in all major cellular
processes.
Genomic Location and Biogenesis
miRNAs are present in introns within coding or non-coding transcribed units, or
as exons, i.e. independent genes. miRNAs may be present as single autonomous miRNA
genes; however, over half of human miRNAs are present as miRNA clusters that are coexpressed as polycistronic units [87]. Members of miRNA clusters frequently target
similar or related genes, culminating in an increased overall effect on a single pathway or
protein complex, rather than broad, unrelated targeting by multiple miRNAs [88-91].
Many miRNA clusters occur because of gene amplifications or insertions, resulting in
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multiple copies of identical or similar sequences [92,93]. This in turn results in nearly
identical targeting patterns. Similarly, related mRNAs harboring binding sites
corresponding to the same miRNA or miRNAs indicates a coordinated mechanism of
gene regulation [94].
The majority of miRNAs are processed from introns of mRNA. Experimental
evidence shows that processing of miRNAs need not occur only after splicing out of the
intron, and that miRNA processing does not affect mature mRNA assembly [95].
Intronic and Exonic miRNAs are transcribed by RNA Polymerase II, and exonic
miRNAs are processed similarly to mRNA, in that they are capped with 5’meG and
polyadenylated. After miRNAs are transcribed, intra-strand regions of complementarity
result in the formation of an imperfect hairpin loop (pri-miRNA). The functional miRNA
sequence is present on the arm of this loop [87]. The biogenesis of this primary transcript
is what differentiates miRNAs from other small interfering RNA within the RNAmediated gene silencing field. Rather than cleavage into multiple small regulatory
molecules, pri-miRNAs are “cropped” in the nucleus into small hairpin structures called
pre-miRNAs. This cropping enzyme is known as the microprocessor, and is comprised of
the class II Ribonuclease III enzyme, Drosha, and DGCR8, a double stranded RNA
binding protein [96]. Cropping by the microprocessor complex is the initiating event of
miRNA processing, as loss of these enzymes leads to accumulation of pri-miRNAs and
reduced pre-miRNA levels. Following microprocessor cropping, pre-miRNAs are
exported to the cytoplasm via Exportin5/RanGTP [97]. Exportin5 is a nuclear transporter
that exports pre-miRNAs in complex with RanGTP. The entire complex is shuttled
across the nuclear membrane to the cytoplasm where RanGAP stimulates hydrolysis of
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GTP to GDP, and the pre-miRNA is released into the cytoplasm [98]. Once in the
cytoplasm, they are cleaved by the class I Ribonuclease III, Dicer, to form imperfect
duplexes. The 3’ overhang of pri-miRNA is recognized by the PAZ domain of Dicer,
and its catalytic RNAse III subunit cleaves the stem loop into a ~22 nt miRNA duplex.
In general, the strand with the least stable 3’ end base pairing functions as the guide
strand while the other strand, often annotated miR*, is degraded. However, both the
canonical guide strand as well as the star strand of several miRNAs have been shown to
be functional.
Mechanism
To effect gene silencing, the guide strand is loaded into the RNA-induced
silencing complex (RISC), which binds target mRNA 3’ Untranslated regions (UTRs) in
a miRNA seed sequence-directed manner [84]. The RISC is a large enzyme complex
whose major functional unit is Argonaute (Ago2). Ago2 is a versatile enzyme involved
in RNA-induced silencing. Perfect complementarity between the silencing RNA and the
mRNA directs mRNA strand cleavage. This is always the case with siRNA, and
occasionally with miRNA-mediated silencing. The mechanism of gene silencing
employed by miRNAs, however, revolves around translational repression, in which Ago2
does not cleave target mRNA [84,99]. Indeed, most miRNA targets are not based on
perfect base pairing; however, the perfect base pairing dictating mRNA cleavage is not a
hard and fast rule. Ago2 has recently been found to associate with P-bodies, and one
potential mechanism of gene silencing may involve sequestering of RISC-associated
mRNA in P-bodies to down-regulate protein expression [99].
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The Argonaute complex is targeted to specific mRNA by base pairing between
the miRNA and the 3’ UTR of the target mRNA [84]. Nucleotides 2-7 on the 5’ end of
the miRNA are known as the seed sequence. Complementarity between these bases and
target mRNA 3’UTRs results in the specific targeting and regulation of those mRNA.
Complementarity is rarely perfect, and binding sites vary in their affinities based on
sequence complementarity, as well as the presence of an Adenosine within the mRNA
UTR in line with the first nucleotide of the miRNA. Canonical sites include the 7merA1, in which there is perfect complementarity between the miRNA seed sequence and the
mRNA, as well as an mRNA adenosine at the first nucleotide position; the 7mer-m8 site,
in which there is perfect base pairing within the seven nucleotides of the seed sequence,
as well as at the 8th nucleotide position, which is not included as part of the canonical
seed sequence; and the 8mer site, in which there is perfect complementarity between the
seed sequence and the 8th nucleotide, as well as an mRNA adenosine at position 1.
Marginal binding sites are 6mers, in which there is complementarity between the miRNA
seed sequence and the target mRNA, but no compensatory adenosine at position 1, and
no match at the 8th nucleotide. Similarly, other 6mers include complementarity at six
contiguous bases that occur only partially within the seed sequence. Targeting is also
enhanced by compensatory complementarity that occurs several bases downstream of the
seed sequence site. This particularly enhances targeting when seed sequence
complementarity contains one or more mismatched bases. Canonical and marginal
complementarity sites are summarized in Table 1.
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Table 1. Canonical and Marginal miRNA binding sites. Lower strand: miRNA
Upper Strand: target mRNA. ORF: Open reading frame, N: complementary
nucleotide, NNNNNN: seed sequence, A: position 1 adenosine.

25

MicroRNAs in Cancer
Because of their regulation of such crucial cell signaling pathways, dysregulation
of miRNAs contributes to disease, for example cancer [100]. Just as protein coding
genes become dysregulated in cancer [82,101], miRNA genes may also become
aberrantly over expressed or silenced [100,102]. miRNAs within introns are subject to
regulation by changes in the promoter controlling the host gene [95]. Other miRNAs
expressed from the genome as independent transcripts may be epigenetically modified at
their promoters to affect expression levels [100,103-107]. miRNAs are also subject to
gene amplification and deletions [108,109].
By targeting one or more tumor suppressors, miRNAs can function as oncogenic
miRNAs (oncomiRs) when aberrantly over-expressed. miR-21 has emerged as a
canonical example of an oncomiR. miR-21 is up-regulated in nearly all epithelial cellderived solid tumors including breast, pancreas, lung, gastric, prostate, colon, head and
neck, and esophageal cancers. It is also reported to be up-regulated in hematological
malignancies such as leukemia, lymphoma and multiple myeloma. miR-21 is overexpressed in glioblastoma, osteosarcoma, and spermatocytic seminoma. Thus, miR-21 is,
as yet, the only gene that is found to be overexpressed in all major classes of human
cancers derived from epithelial cells, connective tissues, hematopoietic cells, or nervous
cells. Its target genes include regulators of apoptosis, cell cycle progression, growth
factor signaling, and proliferation [41]. It has been found to directly target such well
known tumor suppressors as Pten and Bcl2. miR-21 overexpression in MCF-7 human
breast cancer cells promotes colony formation by directly targeting the tumor suppressor
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PDCD4 and suppressing its expression [110]. The role of miR-21 in cancer exemplifies
the diverse targeting and dastardly effects of oncomiRs.
In addition to dysregulation of single exonic miRNA genes, entire miRNA
clusters may be dysregulated in cancer, for example the miR-17~92 cluster is frequently
up-regulated in cancer, specifically, its genomic locus is amplified in diffuse large B-cell
lymphoma [108]. It contains several homologous miRNAs that target pro-apoptotic
genes such as p21 and Bim [100]. Dysregulation of this coordinated targeting of major
cell signaling regulators contributes strongly to the progression of cancer. Overall, the
over-expression of oncogenic miRNAs leads to both the targeting and loss of tumor
suppressive mechanisms.
In contrast, miRNAs may function as tumor suppressors by targeting oncogenes
and regulating their expression. Tumor suppressor miRNAs are often down-regulated in
cancer [100,102]. The let-7 family is a well-studied tumor suppressor miRNA family
comprised of 12 miRNA family members. These family members have been found to
target and regulate expression of the proto-oncogenes Ras and Myc, as well as other
oncogenic proteins such as CDK6 and Cyclin D, cementing its role as a tumor suppressor
by regulating proliferation and crucial cell cycle promoting enzymes [100]. Expression
of the let-7 miRNA family is frequently down-regulated in human lung cancer cases,
which also exhibit higher levels of Ras expression [111]. This is in contrast to cancers
that express mutated, constitutively active forms of Ras, strongly implicating
involvement of let-7 family dysregulation in cancer pathogenesis. Similarly, in 31-64%
of medulloblastomas, the most common central nervous system tumor in children, Myc is
over-expressed; however, the Myc gene is amplified in only 5-8% of medulloblastoma
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cases. The locus containing miR-33b is frequently lost in medulloblastoma, and miR-33b
has been shown to directly target Myc and repress its expression in medulloblastoma cell
lines [112]. These studies provide evidence for the involvement of miRNAs in regulation
of proto-oncogenes, indicating their importance in homeostasis and, in turn, the role their
dysregulation plays in human disease.
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Figure 1. The miR-200 family

Figure 1. The miR-200 family Upper: Genomic organization of miR-200 family.
Lower: miR-200 family grouped by seed sequence
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miR-200a
miR-200a is a member of the miR-200 family. This family is comprised of five
members present in the genome as two clusters (Figure 1). The first cluster is located on
chromosome 1 at locus 1p36.33 and contains miR-200b, miR-200a, and miR-429. The
second cluster is located on chromosome 12 at locus 12p13.31 and contains miR-200c
and miR-141. miR-200a and miR-141 contain identical seed-region sequences of
AACACUG, and miR-200b, miR-200c, and miR-429 contain identical seed sequences
that differ from the other seed sequence by one nucleotide: AAUACUG. Because of
these shared seed sequences, miR-200a and miR-141 are predicted by targeting
prediction algorithms to regulate the same genes. While the entire family is frequently
expressed together and demonstrated to regulate the same targets [113], both clusters do
not always have identical functions [114].
Along with its family members, the first and most well studied function of miR200a is in maintenance of epithelial cell morphology through regulation of the promesenchymal Zeb transcription factors [115,116]. Zeb1 and Zeb2 directly bind the
promoter of the epithelial marker E-cadherin to down-regulate its transcription.
Likewise, Zeb1/2 directly bind the promoter and stimulate transcription of the
mesenchymal marker Vimentin. By regulating these pivotal transcription factors, miR200a promotes epithelial cell morphology, and inhibits the epithelial-mesenchymal
transition (EMT). EMT is the critical initiating step of metastasis and as such, is crucial
in the progression from primary tumor to deadly metastasis [117]. As a potent regulator
of this process, miR-200a is frequently an inhibitor of metastasis, and thus functions as a
tumor suppressor [118,119]. Several studies in cancer cell lines and tumor samples
30

demonstrate the down-regulation of miR-200a in mesenchymal metastatic cells
[105,120,121].
Conversely, emerging studies show cancer cell populations and tumor samples
that over-express miR-200a and rely on its over-expression for metastatic colonization,
growth, and survival [5,62,122,123]. Many of these studies remain focused on EMT and
suppose that maintenance of an epithelial-like morphology by the miR-200 family either
accounts for heterogeneity of tumor cells [124], or promotes a reversal of EMT, allowing
for metastatic colonization at sites distant from the primary tumor [123]. A study in an
isogenic series of breast cancer cell lines with increasing invasiveness and metastatic
potential, demonstrated that the cell line that is able to fully invade, metastasize and
colonize distant organs from the primary tumor site is the only cell line in the series that
expresses the miR-200a family. Targeting of Sec23 by the miR-200 family was
demonstrated to affect the cells’ secretome and regulate the ability of these cells to
invade. The authors concluded that the miR-200a family promotes the ability to colonize
distal sites during metastasis, a novel role for the miRNA family often regarded as a
tumor suppressor. The authors speculated that promotion of an epithelial phenotype is
necessary for establishing metastatic tumors. Another breast cancer cell line study
demonstrated that an enhancer specific to the miR-200b~429 cluster, which also includes
miR-200a, is responsible for high expression levels of miR-200a in epithelial breast
cancer cells [107].
In pancreatic cancer cells, miR-200a has been shown to be hypomethylated and
differentially over-expressed, along with its family member miR-200b [105].
Meanwhile, its canonical target, Zeb1, was found to be hypermethylated and silenced,
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indicating that the consequences of miR-200a overexpression in this pancreatic cancer
model were occurring separately from its role in EMT inhibition via Zeb1 repression.
miR-200a and miR-200b were also found at higher levels in the sera of pancreatic cancer
patients, highlighting the importance of this miRNA in a clinical disease setting, as well
as the potential use of miR-200a and its family members as biomarkers in disease.
A miRNA expression analysis study revealed that miR-200a was expressed at
levels higher in epithelial ovarian cancer samples than in benign cysts. Further
stratification revealed that miR-200a expression was associated with early stage tumors,
and that late stage metastatic tumors expressed significantly lower levels of both miR200a and E-Cadherin [125]. Overexpression of miR-200a in earlier stages of cancer,
rather than the metastatic steps associated with a mesenchymal phenotype, is consistent
with both the established role of miR-200a in promoting an epithelial phenotype as well
as the newer studies that demonstrate a role for miR-200a in proliferation and growth.
Another novel target of miR-200a is Yap1, a key mediator in the Hippo signaling
pathway, and a known regulator of anoikis [62]. miR-200a was found to directly target
Yap1 in breast cancer cells, and overexpression of miR-200a resulted in anoikis
resistance of human breast cancer cells in animal models. By targeting such a crucial
regulator of cell homeostasis, miR-200a was able to enhance metastatic potential of these
breast cancer cells.
miR-200a has also been shown to up-regulate PI3K signaling and Akt activity by
targeting Fog2, which binds and inhibits the regulatory subunit of PI3K [102]. This study
demonstrates a role for miR-200a in promoting cellular growth, unrelated to its role in
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maintenance of an epithelial phenotype. miR-200a has a dichotomous role in the
promotion and inhibition of different metastatic steps, and has an emerging role in
cellular growth and survival.
Hypothesis and Research Strategy
Taken together, it is clear that miRNAs play crucial roles in cancer progression
and are frequently dysregulated during all stages of oncogenesis. It is crucial to study the
molecular events that occur early in cancer progression in order to enhance detection and
diagnostic techniques as well as to aid in cancer prevention. To characterize specific
miRNA roles in cancer initiation, the following hypothesis was proposed:
MicroRNAs function as oncogenes in malignant cell transformation.
In this study, a biphasic approach was employed to characterize the role of
miRNAs in cancer initiation. We first examined the role of miRNAs grouped according
to genomic cluster in four major cancer signaling pathways: AP-1, NF-κB, c-Myc, and
p53. Our second step was to screen miRNAs for the ability to transform epithelial cells.
In our first step, we found that miR-200a directly suppresses p53 and inhibits
apoptosis. In the second step, we found that miR-200a transforms immortalized rat
epithelial RK3E cells, and, when expressed with Ras, miR-200a enhances transformation
of immortalized human epithelial MCF10A cells. Further characterization of the
mechanism behind miR-200a’s ability to transform cells revealed that miR-200a
cooperates with the RalGEF effector pathway of Ras to transform MCF10A cells and
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induce tumorigenicity. Taken together, these results reveal a new role for miR-200a in
malignancy.
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CHAPTER II
A SYSTEMATIC SCREEN REVEALS MICRORNA CLUSTERS THAT
SIGNIFICANTLY REGULATE FOUR MAJOR SIGNALING PATHWAYS.
Chapter Overview
MicroRNAs (miRNAs) are encoded in the genome as individual miRNA genes or
as gene clusters transcribed as polycistronic units. About 50% of all miRNAs are
estimated to be co-expressed with neighboring miRNAs. Recent studies have begun to
illuminate the importance of the clustering of miRNAs from an evolutionary, as well as a
functional standpoint. Many miRNA clusters coordinately regulate multiple members of
cellular signaling pathways or protein interaction networks. This cooperative method of
targeting could produce effects on an overall process that are much more dramatic than
the smaller effects often associated with regulation by an individual miRNA. In this
study, we screened 366 human miRNA minigenes to determine their effects on the major
signaling pathways culminating in AP-1, NF-κB, c-Myc, or p53 transcriptional activity.
By stratifying these data into miRNA clusters, this systematic screen provides
experimental evidence for the combined effects of clustered miRNAs on these signaling
pathways. We also verify p53 as a direct target of miR-200a. This study is the first to
provide a panoramic view of miRNA clusters' effects on cellular pathways.
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Introduction
MicroRNAs (miRNAs) are small RNA molecules 20-25 nucleotides in length.
Through complementary base pairing, miRNAs bind the 3' UTR of target mRNAs to
post-transcriptionally down-regulate gene expression. Originally discovered in C.
elegans, the first miRNA was found to be a key regulator of development [87,126];
however, subsequent studies have revealed a myriad of roles for miRNAs in virtually all
biological processes. Studies highlighting the biological function of miRNAs have
emerged alongside studies that reveal the detrimental effects of miRNA dysregulation
[127]. Many miRNAs, when lost or over-expressed, become crucial players in the
oncogenic process [128,129]. miRNAs may target a wide variety of genes, including
those most closely associated with the processes of cancer development, particularly the
hallmarks of cancer [41,82]. By inhibiting expression of tumor suppressors, miRNAs
may function as oncogenes. Conversely, miRNAs can also exhibit tumor suppressive
properties by repressing oncogenes.
miRNAs are transcribed and processed from intronic or intergenic regions, and
may be transcribed as individual miRNA or as polycistronic transcripts (clusters) [87,95].
Primary miRNA transcripts (pri-miRNA) are processed into imperfect stem-loop
structures called pre-miRNAs by Drosha in the nucleus and then exported into the
cytoplasm by Exportin V. These pre-miRNAs are cleaved by Dicer to form mature
miRNAs, which are then incorporated into the RNA-induced silencing complex (RISC).
Imperfect complementary base-pairing between the miRNA and mRNA directs the RISC
to the 3’ UTR of target mRNA. This targeting leads to down-regulation of translation of
the mRNA, and is often accompanied by a decrease in mRNA levels [87].
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Nearly half of all miRNA genes are within 50 kilobases of another miRNA gene
[88]. These clusters range from 2 miRNAs, for example miR-200c and miR-141, to as
many as 46 miRNAs, as seen in the largest miRNA cluster in primates, Chromosome 19
miRNA Cluster (C19MC) [88,130,131]. miRNAs within clusters frequently contain high
sequence homology, particularly within the seed sequence, resulting in identical targets
[5,123]. Recent evidence, however, points to clustered miRNAs that target different
genes within a specific pathway or protein complex [89,132]. miRNAs are also predicted
to target downstream effectors of cellular signaling pathways such as second messengers
and transcription factors (TFs) more frequently than upstream ligands and receptors or
housekeeping and structural genes [133]. TFs are key players in cell signaling pathways.
By responding to a plethora of extra- or intra-cellular stimuli and regulating transcription
of the many genes necessary for a cellular response, TFs act as crucial cell signaling
hubs. Dysregulation of major TFs is often a key event in oncogenesis [134]. Such TFs
include AP-1, NF-κB, c-Myc, and p53 [57,135-137]. Many individual miRNAs target
these pathways [138-141], but little data exists regarding the full effect of miRNA
clusters. While it is clear that miRNA clusters are frequently predicted to target specific
cell signaling pathways, no experimental evidence based on systematic screening has
been provided. In this study, we intend to address these deficiencies by analyzing the
role of 366 human miRNAs as clusters in these four major signaling pathways using an
existing genetic library [142].
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Experimental Procedures
miRNA Screen
The method involves a published lentiviral-based miRNA genetic library that
contains a large number of human miRNA minigenes [142]. To screen miRNAs that
specifically target TFs of interest, we utilized luciferase constructs plus the miRNA
library. For instance, pTRF-p53-Luc (Systems Biosciences) contains a firefly luciferase
gene (luc) under the control of a minimal CMV promoter. This promoter is only
activated when p53 binds to the p53-specific transcription response elements (TREs),
eight tandem repeats of ACATGTCCCAACATGTTGTCG. Similarly, TRE constructs
for the other TFs are as follows: pTRF-NF-κB-Luc: four repeats of GGGGACTTTCC;
and pTRF-AP1-Luc: four repeats of TCCGGTGACTCAGTCAAGCG. c-Myc activity
was measured using an E2F2-Luc reporter vector consisting of the E2F2 promotor with
four distinct E-boxes, CACGTG [143]. The parental vector, pSIF[142], substituted for
the miRNA construct, serves as a normalization control for miRNA expression. Rluc
from pRL-TK (Promega) is used to normalize transfection efficiency and total protein
synthesis.
Cell Culture Experiments
293T and H1299 cells (American Type Culture Collection, Manassas, VA) were
cultured in DMEM media supplemented with 10% FBS and antibiotics at 37°C with 5%
CO2. Lipofectamine LTX (Invitrogen) was used for all transfections according to
manufacturer’s instructions. Luciferase assays were conducted using the Dual-Glo®
Luciferase Assay System (Promega) 48 hours post-transfection in 96-well plates.
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Relative Luciferse Units (RLU) were normalized to Renilla luciferase expression. The
parental vector pSIF was used to normalize plate-to-plate variation. Apoptosis was
measured using an ApoTarget™ Annexin-V FITC Apoptosis Kit (Invitrogen, Carlsbad,
CA) as described previously [142]. Briefly, transfected cells were washed twice with
PBS, resuspended in Annexin-V binding buffer, and then incubated in Annexin-V FITC
and Propidium Iodide Buffer in the dark for 15 minutes at room temperature. Stained
cells were then analyzed on an LSR II flow cytometer (BD Biosciences) using FL1
(FITC) and FL3 (PI) lines. Cell cycle was analyzed as described [144]. Experimental
groups were analyzed in triplicate, and data represent three independent trials.
Western Blot
Total protein was isolated from cells in 6-well plates using M-PER mammalian
protein extraction reagent (PIERCE, Rockford, IL). Protein concentration was measured
using a BCA kit (PIERCE, Rockford, IL). 30-50 µg of protein were separated on 12% to
15% Bis-Tris polyacrylamide gels (Bio-Rad, Hercules, CA) and then transferred to
PVDF membranes (Bio-Rad). Protein membranes were incubated in blocking buffer (1×
Tris-buffered saline, pH 7.5, 5% nonfat dried milk, 0.05% Tween 20) for 2 hours at
room temperature, followed by anti-p53 antibody (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA), or anti-β-actin antibody (Sigma-Aldrich) overnight at 4 0C. The membranes
were washed with 1× Tris-buffered saline containing 0.05% Tween 20, incubated with
horseradish peroxidase-linked goat anti-mouse Ig (Santa Cruz) or goat anti-Rabbit Ig
(Cell Signaling) for 1 hour at room temperature, washed, and visualized with the
SuperSignal West Dura/ Femto Chemiluminescent Substrate kit (PIERCE).
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Statistical Analysis
Boxplots of the luciferase results for all clusters were plotted to show what the
observations look like for each end point variable (AP-1, NF-κB, c-Myc, or p53). For
each end point, residual plots indicated that the observations with log-transformation are
more likely to be normally distributed and have equal variances among different clusters.
For each variable, one way analysis of variance (ANOVA) was applied to examine
whether the observations at log-scale from different clusters are significantly different
from the overall means at log scale. Residual plots indicated that the log-transformed
responses are more likely to be normally distributed and have equal variances among
different clusters. The Fisher’s least significant difference tests were applied to examine
which clusters are significantly different from the overall least square mean [145]. Based
on the analytic results, we painted the boxplots red for the clusters with significantly high
readings (observations), and green for the clusters with significantly low readings. The
clusters with a pink diamond are significantly different from the overall mean (Figures 36).
Results
miRNA Library Screening
We used an established TF luciferase-based screen to determine miRNAs
affecting pathways that regulate TF activity (Figure 2). 293T cells were transfected in
triplicate with a plasmid containing a firefly luciferase gene under the control of a
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minimal CMV promoter along with a second plasmid containing a member of our
miRNA library [142]. Transcription response elements (TRE) corresponding to each TF
were placed upstream of the promoter. A third plasmid containing a Renilla luciferase
gene driven by the HSV-TK promoter served as a normalization control. Luciferase gene
expression was measured with a luminometer to determine which miRNA expression
resulted in inhibition or promotion of TF activity. Luciferase expression was normalized
to Renilla luciferase to yield Relative Luminescence Units (RLU) for each miRNA before
being normalized to the parental vector. This approach has been used to identify
individual miRNAs in the p53, NF-κB, and c-MYC pathways [142,144,146]. To analyze
the impact of miRNA clusters in reporter activities, mean RLU values for each cluster
were calculated and normalized to the mean values of all miRNAs. This allowed us to
determine statistical significance of miRNA regulation of specific TFs when miRNA data
were stratified into clusters compared to baseline overall miRNA effects. For each TF,
clusters with values significantly lower than the overall cluster mean were identified as
down-regulators of the specified TFs. Clusters with values significantly higher than the
cluster mean were deemed up-regulators of the specified TF.
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Figure 2: Schematic of luciferase-based microRNA screen.
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Figure 2: Schematic of luciferase-based microRNA screen. 293T cells were cotransfected with: 1) a vector containing a luciferase gene under control of regulatory
elements recognized by AP-1, NF-kB, p53, or c-Myc; 2) a member of our microRNA
library, and 3) a Renilla luciferase vector for normalization of luciferase values.
Following transfection, cells were analyzed by luciferase assay to measure the effects
of miRNA regulation of TF-driven luciferase expression.
TRE: Transcription factor regulatory element, TF: Transcription factor, luc: luciferase,
Rluc: Renilla luciferase, UTR: Untranslated region
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AP-1
Activating protein 1 (AP-1) is a dimeric TF consisting of Jun, Fos, or Activating
TF (ATF). Combinations of these subunits allow for hetero- and homo-dimerization,
resulting in differing DNA recognition and functions of AP-1. The TRE used in this
screen is predominantly recognized by the cJun-cFos as well as cJun homodimers to a
lesser extent [147,148]. AP-1 is activated in response to many signals such as stress,
bacterial and viral infections, cytokines, growth factors, and oncogenic stimuli. Posttranslational regulation occurs through interactions with other TFs, proteolytic turnover,
and phosphorylation [147,149]. Data from the miRNA screen point to five miRNA
clusters that yield an overall negative effect on AP-1 directed transcription (Figure 3 and
Table 2). These clusters may target genes that are upstream of the pathway directly
regulating AP-1 turnover, or genes within signaling cascades that lead to AP-1 activation.
Five clusters were found to have an activating effect on AP-1 transcriptional activity.
One such noteworthy cluster is 10a~196a. Studies have established a pro-proliferative
role for this cluster in multiple cancers including pancreatic cancer and acute myeloid
leukemia [150-152]. This role is consistent with our finding that it positively regulates
activation of a TF known for its role in promoting proliferation, particularly in the
context of cancer [147].
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Figure 3. Boxplot showing logarithmic values of AP-1-mediated luciferase
expression for microRNAs grouped according to cluster.
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Figure 3. Boxplot showing logarithmic values of AP-1-mediatedluciferase
expression for microRNAs grouped according to cluster. Clusters that yielded
values significantly different from the overall mean are marked with a pink diamond
and annotated in Table 1. MicroRNA clusters that caused significant up-regulation of
AP-1-driven luciferase gene expression are highlighted in red. MicroRNA clusters
that down-regulated this expression are marked in green. 293T cells were transfected
with the indicated miRNA in triplicate. NC: non clustered miRNAs.
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NF-κB
NF-κB is a TF that consists of Rel protein dimers that bind κB sites in the
promoters of target genes to regulate transcription. The Rel family of proteins consists of
five members: p100 and p105 which are proteolytically processed into p50 and p52,
respectively, and RelA, RelB, and c-Rel, which do not require proteolytic processing.
The TRE in this screen is specifically recognized by the heterodimer made up of p50 and
RelA, which is the most abundant form of NF-κB in most cells. This heterodimer is held
inactive in the cytoplasm by inhibitors of κB (IκB) [139]. The classical pathway of NFκB activation is triggered by exposure to bacterial or viral infections and proinflammatory cytokines such as TNF-α. These signals go through the Toll-like receptor
(TLR) to activate IκB kinases (IKK) which phosphorylate IκB, targeting it for ubiquitinmediated degradation. NF-κB is released and translocates to the nucleus to promote
transcription [139,153]. One of the major functions of NF-κB is inhibition of apoptosis,
though its role in cancer development and progression is cell-type dependent.
Suppression of NF-κB activation abrogates transcription of critical anti-apoptotic genes
such as c-FIIP, cIAP1, cIAP2, and BCL-XL [153]. This screen revealed seven clusters
that negatively regulate NF-κB-mediated transcription (Figure 4 and Table 2). Inhibition
of NF-κB signaling implies a potential anti-inflammatory role for these clusters. Five
clusters were found to up-regulate NF-κB activity. Among these is cluster 454~301a.
miR-301a has recently been implicated as an NF-κB inducer in pancreatic cancer [142].
Cluster 99b~125a was also found to up-regulate NF-κB activity. A recent study found
that miR-125a and miR-125b directly target TNFAIP3, a ubiquitin editing enzyme that
negatively regulates NF-κB activity by disrupting the activation of IKK [120].
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Figure 4. Boxplot showing logarithmic values of NF-κB-mediated luciferase
expression for microRNAs grouped according to cluster.
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Figure 4. Boxplot showing logarithmic values of NF-κB-mediated luciferase
expression for microRNAs grouped according to cluster. Clusters that yielded
values significantly different from the overall mean are marked with a pink diamond
and annotated in Table 1. MicroRNA clusters that caused significant up-regulation of
NF-κB-driven luciferase gene expression are highlighted in red. MicroRNA clusters
that down-regulated this expression are marked in green. 293T cells were transfected
with the indicated miRNA in triplicate. NC: non clustered miRNAs.
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c-Myc
c-Myc is a TF that heterodimerizes with Max to bind E-boxes within the
promoters of its target genes [154]. It is a multifunctional protein that regulates a wide
variety of cellular processes such as cell cycle progression, growth and metabolism,
differentiation, and apoptosis [134]. Because of its function in positively regulating
processes that contribute to tumorigenesis, Myc is a proto-oncogene. Aberrant
expression of Myc is seen in the majority of cancers, resulting from genomic
amplification, or lack of negative regulatory pathways [154]. Our screen returned four
miRNA clusters that down-regulate Myc-induced transcription (Figure 5 and Table 2).
Notably, Cluster 512~519a negatively regulates Myc-mediated transcriptional activation.
Also striking was up-regulation of Myc-mediated transcription by the entire miR-200
family (Clusters 200c~141 and 200b~429). In addition, we have confirmed miR-33b as a
bona fide c-Myc regulator [146].
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Figure 5. Boxplot showing logarithmic values of c-Myc-mediated luciferase
expression for microRNAs grouped according to cluster.
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Figure 5. Boxplot showing logarithmic values of c-Myc-mediated luciferase
expression for microRNAs grouped according to cluster. Clusters that yielded
values significantly different from the overall mean are marked with a pink diamond
and annotated in Table 1. MicroRNA clusters that caused significant up-regulation of
c-Myc-driven luciferase gene expression are highlighted in red. MicroRNA clusters
that down-regulated this expression are marked in green. 293T cells were transfected
with the indicated miRNA in triplicate. NC: non clustered miRNAs.
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p53
p53 has long been known as the guardian of the genome. Its transactivational
functions are well studied and include induction of proapoptotic genes like Puma, Noxa,
and Bax as well as cell cycle regulatory proteins such as p21 [49]. p53 is maintained at
low basal levels in the cell by its inhibitory protein, Mdm2 [155]. Mdm2 inhibits p53
function by acting as an ubiquitin ligase to target p53 for proteasomal degradation as well
as by binding and blocking the DNA binding domain of p53, inhibiting its activity as a
TF. Upon detection of DNA damage, oncogene hyperactivation, or other cellular
stresses, p53 is phosphorylated on its N-terminus, which blocks inhibition by Mdm2 and
promotes its binding to p53 response elements. In our screen, we found 7 miRNA
clusters that significantly up-regulate p53-mediated luciferase expression (Figure 6 and
Table 2). Among these is Cluster512~519a, also known as C19MC. Comprised of 46
pre-miRNAs, it is the largest miRNA cluster conserved in primates. It is an imprinted
gene, and the paternal allele is expressed specifically in the placenta [130,156]. This
tissue specificity is noteworthy in the context of its up-regulation of p53 activity.
Enhanced apoptosis and increased p53 expression in the placenta during pregnancy are
associated with fetal growth restriction, preeclampsia, intrauterine growth restriction, and
HELPP syndrome [157,158]. Our screen implicates a role for this miRNA cluster within
the tightly regulated process of developmental or pathological apoptosis. Among the 5
clusters that down-regulated p53-mediated luciferase expression is 200b~429, one of two
clusters that comprise the miR-200 family (Figure 6 and Table 2). The miR-200 family is
largely known as tumor suppressive because of its inhibition of the epithelialmesenchymal transition (EMT) through direct targeting of Zeb1 and Zeb2 TFs [116,159].
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Our data support an oncogenic role for this miR-200 family and we performed ensuing
studies to examine the role of miR-200a in the p53 pathway (see below). Cluster
25~106b also significantly down-regulated p53 activity, and we noted that miR-25 has
been verified to directly target p53 [144].
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Figure 6. Boxplot showing logarithmic values of p53-mediated luciferase
expression for microRNAs grouped according to cluster.
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Figure 6. Boxplot showing logarithmic values of p53-mediated luciferase
expression for microRNAs grouped according to cluster. Clusters that yielded
values significantly different from the overall mean are marked with a pink diamond
and annotated in Table 1. MicroRNA clusters that caused significant up-regulation of
p53-driven luciferase gene expression are highlighted in red. MicroRNA clusters that
down-regulated this expression are marked in green. 293T cells were transfected with
the indicated miRNA in triplicate. NC: non clustered miRNAs.
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Table 2. Top microRNA clusters that significantly modulate reporter expression.

AP-1

NF-κB

c-Myc

p53

Inhibiting
Clusters
Let7g~135a
125b~100
34bc
513~514
339~329
215~194
30bd
125b~100
206~133b
217~216b
513~514

Difference
from mean
-0.78068
-0.65192
-0.59466
-0.3289
-0.23763
-1.17405
-0.87412
-0.75574
-0.74421
-0.68132
-0.41319

p-value
5.14E-03
1.92E-02
3.26E-02
3.05E-02
3.22E-03
1.90E-04
9.13E-03
2.40E-02
2.62E-02
4.17E-03
2.39E-02

195~497

-0.66248

3.15E-02

193b~365

-0.54136

512~519a
132~212

Activating
Clusters
512~519a
217~216b
10a~196a
454~301a
650
99b~125a
181cd
192~194
650
454~301a

Difference
from mean
0.183747
0.567326
0.596606
1.399706
1.636268
0.822977
0.839874
1.167321
1.262463
1.876999

p-value
1.78E-02
4.14E-02
3.20E-02
3.86E-04
3.57E-05
2.81E-03
1.22E-02
1.33E-02
7.49E-03
7.89E-05

17~92a

0.305999

1.74E-02

1.35E-02

23b~24

0.368437

4.00E-02

-0.52607

8.16E-17

16~15a

0.432454

4.80E-02

-0.52607

1.63E-02

200c~141

0.589838

1.08E-03

200b~429

0.312486

5.25E-03

200b~429

-0.83273

6.44E-04

532~500

0.295012

2.61E-02

30ec

-0.69189

4.46E-03

512~519a

0.444204

1.78E-10

425~191
653~489
25~106b

-0.61609
-0.56796
-0.53544

1.12E-02
1.93E-02
7.25E-03

99a~125b
296~298
371~373

0.522585
0.712016
0.747797

3.12E-02
3.71E-02
2.14E-03

454~301a

0.766234

2.49E-02

650

0.877633

1.03E-02
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miR-200a
The miR-200 family is comprised of two clusters (Figure 1). Cluster 200b~429 is
located on chromosome 1 and contains miR-200a, miR-200b, and miR-429. Cluster
200c~141 is located on chromosome 12 and contains miR-200c and miR-141. The most
thoroughly studied function of the miR-200 family is inhibition of EMT. EMT is
characterized by cellular acquisition of mesenchymal morphology and phenotypes and is
largely associated with tumor metastasis. In particular, the TFs Zeb1 and Zeb2 are
responsible for repressing transcription of E-cadherin and other epithelial markers to
promote EMT [115,160]. The miR-200 family directly targets the 3' UTRs of Zeb1 and
Zeb2 to inhibit their expression, and Zeb1 and Zeb2, on the other hand, bind the
promoters of both miR-200 family clusters to reciprocally inhibit their transcription
[124]. This miRNA family inhibits proliferation as well as EMT through its targeting of
Zeb1 and Zeb2 [161]. Recently, however, new tumor-suppressor targets of the miR-200
family have been discovered, suggesting this miRNA family may have a pro-proliferative
function [5,102,162]. In addition, a recent study has investigated the miR-200 family’s
promotion of an epithelial morphology in the context of a mesenchymal-epithelial
transition, thus promoting metastatic colonization, and providing further evidence for an
oncogenic role for this miRNA family [123].
Our screen revealed a p53-suppressing role for cluster 200b~429, which contains
miR-200a, miR-200b, and miR-429. TargetScan predicts a miR-200a binding site in the
3’ UTR of p53 (Figure 7A). This predicted target is conserved between humans and
chimpanzees. To determine direct targeting of p53 by miR-200a, a luciferase assay was
performed using constructs with a wild type 3’ p53 UTR (WT) or a 3’ UTR with a
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mutated miR-200a binding site (Mut) downstream of a luciferase reporter gene.
Luciferase assay was performed to measure differential reporter expression resulting
from this binding site mutation in p53-null H1299 cells (Figure 7B). Compared to empty
vector control, miR-200a caused a significant reduction in WT construct luciferase
expression. This reduction of expression was not seen in cells with the mutant 3’ UTR.
This suggests that miR-200a directly targets the 3’ UTR of the human p53 gene. Western
blot was performed to determine the effects of miR-200a on p53 protein levels. H1299
cells were transfected with miR-200a or its empty vector control, and either p53 coding
sequence with a wild type 3’ UTR (WT) or that with a mutated miR-200a binding site in
its 3’ UTR (Mut). Compared to the control, miR-200a caused a significant downregulation of p53 protein levels in cells with a WT 3’ UTR, but not those with a Mut 3’
UTR (Figure 8A). These results show that direct targeting of the p53 3’ UTR by miR200a down-regulates p53 at the protein level. To determine the functional significance of
p53 suppression by miR-200a, we analyzed apoptosis and cell cycle in response to miR200a over-expression in H1299 cells containing a p53 expression cassette with either WT
or Mut 3’ UTR. We found that re-expression of p53 in H1299 cells led to significant cell
apoptosis and cell cycle arrest at the G1 phase (G1 arrest) even in the absence of DNA
damage (Figure 8B and 8C), in agreement with previous reports [163-165].

miR-200a

significantly decreased apoptosis in H1299 cells with the WT p53 construct (Figure 8B).
Apoptosis was unaffected in cells containing the Mut p53 construct. In addition, G1
arrest was also inhibited by miR-200a compared to the vector control (50.7% versus 60.1,
P≤0.05) only when the exogenous p53 had a WT 3’ UTR (Figure 8C). Taken together,
these results provide a new mechanism of oncogenic action for miR-200a. By directly
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targeting the 3’ UTR of p53, miR-200a down-regulates p53 protein expression, resulting
in a significant reduction in apoptosis and G1 arrest.
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Figure 7. miR-200a directly targets the human p53 gene.
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Figure 7. miR-200a directly targets the human p53 gene. (A) Schematic
representation of miR-200a: p53 3'UTR. Top: seed sequence base paring between
miR-200a and the 3'UTR of p53 mRNA. Bottom: p53 constructs with the wild type
miR-200a binding site (WT) or a mutated miR-200 binding site (Mut) in the 3'UTR.
(B) A reporter assay to determine whether the p53 3'UTR is targeted by miR-200a. Y
axis denotes relative luminescent units (luc/Rluc) in H1299 cells expressing WT or
Mut p53 3'UTR constructs and miR-200a.
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Figure 8. miR-200a downregulates p53 protein expression and inhibits apoptosis.
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Figure 8. miR-200a downregulates p53 protein expression and inhibits apoptosis.
(A) Western blotting analyses of H1299 cell extracts. H1299 cells were transfected
with miR-200a and WT or Mut p53 3’UTR constructs. (B) Apoptosis assay of H1299
cells transfected as in C. E. Cell cycle analysis of H1299 cells transfected as in (C) The
Y axis denotes events (the number of cells) and the X axis denotes the emitted
fluorescent light of the DNA dye (PI), that is, DNA content. Values like indicate the
percentages of cells in the G1 phase with standard error of the mean. *P≤0.05 with
n=3.
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Discussion
Most miRNA studies revolve around finding novel targets of single miRNAs, yet
half of all miRNAs are co-expressed as clusters [88]. Most of the miRNAs within
clusters are likely to be transcribed as a whole unit, so these coexpressed miRNAs shall
be investigated together for their biological and pathological function. By stratifying our
screen of miRNAs that target TF signaling pathways into miRNA clusters, we were able
to collect data that describes the effects of an entire miRNA cluster on a signaling
pathway culminating in regulation of a major TF. Several mechanisms exist behind
multiple coexpressed miRNAs regulating a wide variety of targets, thus the modus
operandi of miRNA clusters is not fully understood. Individual miRNAs are predicted
to, and have been found to target a wide array of genes and affect multiple cellular
functions [41,166]. Based solely on this, a miRNA cluster could potentially target any
and all cell signaling pathways. However, bioinformatics, as well as an increasing
number of molecular biology approaches have parsed out a much more ordered pattern of
target suppression by miRNA clusters [89-91,133]. miRNA clusters are predicted to
target interacting members of protein complexes [89], multiple proteins within a single
pathway or biological process [90,133], or multiple clustered miRNAs may
simultaneously target and strongly repress a single key regulator of a pathway [167]. In
this way, rather than the small scale fine tuning of hundreds of targets [87], a cluster
would provide a large combinatorial impact on an entire biological process or pathway.
In miRNA clusters comprised of closely related family members, for example both
clusters of the miR-200 family or many members of C19MC, similar or same seed
sequences provide a clear mechanism for multiple cluster members to target identical sets
62

of genes [123]. This combinatorial system of multiple clustered miRNAs regulating an
entire system does not preclude the presence of a single major effector miRNA within a
cluster regulating a specific pathway [90]. Xu and Wong propose this mechanism for
cluster mmu-miR-183-96-182, which is predicted to control 12 signaling pathways. miR96 is predicted to target the majority of the genes within these pathways, indicating it as
the major effector miRNA of this cluster [90]. Cluster 17~92a, is a well-studied
oncogenic cluster whose most oncogenic member, miR-19, has been experimentally
validated as the most active player in the oncogenic process [168]. The 25~106b cluster,
an ortholog of 17~92, significantly down-regulated p53 reporter activity. We have
verified that miR-25 directly targets the p53 gene [144]. It is noted that each miRNA in
the 25~106b cluster is upregulated in multiple myeloma, a cancer with little p53 mutation
[169]. miR-25 is the most significantly upregulated miRNA in multiple myeloma, and its
expression is inversely correlated with p53 mRNA levels, suggesting that miR-21
upregulation could be responsible for p53 inactivation in cancers without p53 mutation
[144]. How other members of the 25~106b cluster upregulate p53 transactivational
activities, however, remains elusive. Similarly, we have verified that miR-301a upregulates NF-κB by inhibiting Nkrf [142], yet the role of miR-454 (the other member of
the 301a~454 cluster) in the NF-κB pathway needs further investigation.
We experimentally pursued the down-regulation of p53 activity by cluster
200b~429 and demonstrated the direct targeting of p53 by miR-200a. miR-200a and its
orthologs, miR-200b, miR-200c, and miR-141 were first found tumor suppressors as they
inhibit EMT through targeting Zeb1 and Zeb2 [115,116]. Recently, studies have begun
investigating the role of miR-200a in the reverse process, mesenchymal-epithelial
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transition, which enhances the metastatic potential of cancer cells [123]. Downregulation of p53 and subsequently apoptosis and G1 arrest by miR-200a illuminates a
novel function for this miRNA. This, coupled with emerging studies that show evidence
for an oncogenic function for miR-200a and its family members [5,102,162], provides a
strong foundation for the oncogenic potential of miR-200a.
While our screen provides new, preliminary experimental data regarding the
effects of miRNA clusters on TF pathways, there are several limitations that must be
considered. First, this screen was performed with a single cell line (293T), which does
not account for any bias that may arise from tissue or cell-type specific targeting.
Second, our screen may return false negatives or positives because other cellular changes
may compromise the luciferase reading. For example, miR-34c is a tumor suppressor,
identified as such by its direct targeting and repression of c-Myc [168]. However, cluster
34bc was not found in this screen to down-regulate c-Myc activity. Finally, single
transient transfections of miRNA-containing plasmids do not replicate endogenous
miRNA levels, which may be subject to further regulation when the entire cluster is
expressed. This may bias the screen toward miRNAs that are expressed at low
endogenous levels. These limitations can be mitigated by further experimental validation
using multiple cell lines or performing miRNA inhibition experiments [144,146].
To summarize, this study provides a panoramic view of miRNA clusters’ effects
on AP-1, NF-B, c-Myc, and p53 signaling pathways and will serve as a base for
thoroughly interrogating the contribution of miRNAs in these pathways.
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CHAPTER III
THE ROLE OF MIR-200A IN MAMMALIAN EPITHELIAL CELL
TRANSFORMATION
Chapter Overview
Cancer is a multistep disease that begins with malignant cell transformation and
frequently culminates in metastasis and death. MicroRNAs (miRNAs) are small
regulatory 21-25-nt RNA molecules and are frequently dysregulated in cancer. miR-200a
is a member of the miR-200 family, which are known to be strong inhibitors of the
epithelial to mesenchymal transition. As such, the tumor suppressive role of miR-200a in
oncogenesis has been well studied; however, recent studies have found a proliferative
role for this miRNA as well as a pro-metastatic role in the later steps of cancer
progression. Little is known about the role of this miRNA in the early stages of cancer,
namely, malignant cell transformation. Here we show that miR-200a cooperates with
Ras to enhance malignant transformation of immortalized mammary epithelial cells.
Furthermore, miR-200a induces cell transformation and tumorigenesis in
immunocompromised mice by cooperating with a Ras mutant that activates only the
RalGEF effector pathway, but not Ras mutants activating PI3K or Raf effector pathways.
This transformative ability is in accordance with miR-200a targeting Fog2 and p53 to
activate Akt and directly repress p53 protein levels, respectively. These results
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demonstrate a role for miR-200a in malignant cell transformation and provide a specific
cellular context where miR-200a acts as an oncomiR rather than a tumor suppressor by
cooperating with an oncogene in the classical two-hit model of malignant cell
transformation.
Introduction
Cancer is an often fatal disease that requires multiple steps to progress from a
normal state to full phenotypic disease [1,170]. Cancer mortality, while comprising one
quarter of all deaths in the United States, is declining, due largely to improvements in
screening and detection. Diagnosis of early stage cancer is strongly associated with
better survival [1-3,171]. Thus it is crucial to understand the molecular events that occur
early in this progressive disease.
Malignant cell transformation is the initiating step of cancer progression [172].
During this process, a cell must bypass senescence and avoid apoptosis, allowing for
uncontrolled proliferation, which leads to formation of a primary tumor [12]. The hyperproliferative, anti-apoptotic phenotypes that arise during malignant cell transformation
are conferred by genetic mutations and abnormalities that upregulate proto-oncogene
activity and ablate tumor suppressor gene function [173]. The first oncogene/tumor
suppressor combinations associated with cell transformation were investigated by in an
attempt to delineate endogenous, non-viral proto-oncogenes [79,81]. The classical model
of cell transformation identified the cooperation between the Ras and Myc oncogenes in
selecting for a dominant-negative p53 tumor suppressor mutation and transforming
primary rodent cells [81]. Numerous transforming oncogenes and tumor suppressor
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mutations have been identified since these landmark studies [82], demonstrating the
complexity of cancer initiation.
Recently, noncoding RNAs, e.g. microRNAs (miRNAs), have garnered interest as
potent mediators of malignant cell transformation and cancer progression [100,106,129].
miRNAs are a regulatory class of small RNAs that bind the 3’ UTR of target mRNA to
post-transcriptionally repress gene expression [84]. miRNAs are frequently dysregulated
in cancer through altered epigenetic modifications, deletions, translocations, and
amplifications [100,103]. The subsequent changes in expression patterns and/or function
result in differential repression of target genes. By repressing expression of oncogenes or
tumor suppressors, a miRNA may function as a tumor suppressor or oncogene,
respectively [129].
Among miRNAs dysregulated in cancer, miR-200a has emerged as a key
mediator of the oncogenic process, though its overall role during cancer progression is
not clear. Gene expression profiling reports that miR-200a is frequently down-regulated
in cancer, including melanoma, breast, and nasopharyngeal cancers [118,119,121]. Its
most well studied function is the suppression of Zeb1/2 transcription factors to inhibit the
epithelial to mesenchymal transition (EMT) and promote a more stable, epithelial
phenotype [115,124]. EMT is a crucial early step in the progression of transformed
primary tumor cells into invasive metastatic cells that invade local stroma, travel through
vasculature, and colonize distant sites in the body [4,174]. These metastases are
responsible for the gross majority of cancer related deaths [171]. By blocking EMT and
inhibiting metastasis, miR-200a functions as a tumor suppressor [116,124].
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However, miR-200a has also been found to promote oncogenesis. miR-200a is
overexpressed in several cancers including endometrial, pancreatic, and ovarian cancers
[105,175,176]. Our studies demonstrate a specific role for miR-200a in early cancer
progression that may apply to such clinical cases. Recent studies show that mesenchymal
to epithelial transition (MET), the reversal of EMT, is a later step in metastasis that
allows motile, invasive cells to revert back to a stable epithelial phenotype more
conducive to forming new metastatic tumors at distant sites [177]. By inducing an
epithelial phenotype in this context, miR-200a promotes metastasis [5,123,178]. In
addition to its involvement in EMT/MET, a limited number of studies have observed a
hyper-proliferative role for miR-200a including stimulation of PI3K signaling in
hepatocellular carcinoma cells and up-regulation of miR-200a in a rat model of
hepatocellular carcinoma [102,179]. My recent study demonstrates the anti-apoptotic
function of miR-200a due to its direct targeting of p53 [53] (Chapter 2). In this study, we
determined the effect of miR-200a overexpression on transformation of rodent cells and
immortalized human MCF10a cells and characterized the underlying mechanism of the
ability of miR-200a to cooperate with Ras to transform MCF10a cells.
Experimental Procedures
Cell Culture
Rat kidney epithelial RK3E cells and human embryonic kidney 293T cells
(American Type Culture Collection, Manassas, VA) were cultured in DMEM media
supplemented with 10% FBS and antibiotics at 37°C with 5% CO2. Human mammary
epithelial MCF10A cells were cultured in DMEM/F12 supplemented with 5% horse
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serum, 20 ng/mL EGF (Invitrogen), 0.5 mg/mL Hydrocortisone (Sigma), 100 ng/mL
Cholera Toxin (Sigma), 10 ug/mL Insulin (Humulin), and antibiotics at 37°C with 5%
CO2.
miRNA Screen
RK3E cells were transfected using Lipofectamine LTX/Plus reagent according to
manufacturer instructions with individual miRNAs from our laboratory’s miRNA library
comprised of 366 human miRNA minigenes in the lentiviral PSIF vector [180]. After 48
hrs, wells were visually inspected for three dimensional foci formation.
Transfection and Viral Transduction
Lipofectamine LTX-plus (Invitrogen) was used for all transfections according to
manufacturer's instructions. For lentivirus production, 293T cells were transiently cotransfected, 24hrs post plating in 6-well plates, with 2µg of pSIF vector, or miRNA,
1.4µg of pVGV-S and 0.7µg of pFIV-34N packing and expression vectors, respectively.
Lentivirus-containing supernatant was collected after 48 hours, centrifuged to remove
cellular debris, and supplemented with 8 µg/mL Polybrene (American Bioanalytical)
before transducing target MCF10A or RK3E cells. For retrovirus production, 3 µg of the
retroviral vectors containing constitutively active RasG12V mutant (Addgene plasmid
1768), c-Myc (Myc construct from Addgene plasmid 16011 cloned into plasmid 12269),
p53dd (Addgene plasmid 9058), or RasG12V effector pathway mutants (Addgene
plasmids 12274, 12275, 12276) [18] were transfected into Phoenix-Ampho cells, and
virus collection and transduction were performed as for Lentivirus. G418 (200 µg/mL),
Puromycin (1 µg/mL), or Hygromycin (8 µg/mL) were used to select for positively
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transduced cells. Cells were transduced three timesmiR-200a expression levels, as
measured by Taq-Man QRT-PCR expression assay (Invitrogen), ranged from a 5 to 15
fold increase above vector control (Data not shown).
Acini Formation in Matrigel

Matrigel (Corning) was used to coat the well bottoms of a 12-well chamber slide
(Ibidi). 5,000 positively drug-selected exponentially growing MCF10A cells suspended
in 2% Matrigel were layered over top of the first Matrigel layer and allowed to grow 5 or
14 days. Acini were fixed with ethanol while still in Matrigel to prevent disruption of
morphology, blocked with goat serum and incubated first with anti-E Cadherin or
Cleaved caspase-3 antibodies (Cell Signaling) overnight at 4° and then Alexa488-coupled
goat anti-rabbit secondary antibodies for 2 hrs room temperature. Slides were visualized
by confocal microscopy.

Colony formation assay
Six well plates were coated with a bottom layer of 0.5% noble agar (SigmaAldrich) and 2000 RK3E or MCF10A cells were suspended in a top layer of 0.2% noble
agar in triplicate. The cells were maintained at 37˚C in a humidified 5% CO2 atmosphere
for two weeks. Fresh media was added at regular intervals to prevent the plates from
drying out. Resulting colonies were stained with 0.05% Crystal Violet and destained
with water. Colonies were counted and imaged using a dissection microscope coupled to
a digital microscope imager (Celestron). The experiment was performed three times,
once for each level.
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Cell Cycle Analysis
For synchronization, MCF10A cells were progressively deprived of serum and
growth factors over 24 hours, then stimulated with complete media for 18 hours. Cells
were collected by trypsinization and washed twice in 1X PBS. Cells were fixed in 1ml of
ice-cold 70% ethanol at 4˚C overnight. Cells were then washed twice with 1X PBS and
stained with a solution of 50 µg/ml Propidium Iodide, 100 µg/ml Ribonuclease A, and
0.2% Triton X-100 diluted in PBS for 30 mins at 4˚C. Flow cytometry was performed
with a FACScan Flow Cytometer. A minimum of 10,000 cells per sample were collected
and the FACS files were analyzed using FlowJo software (Tree Star Inc.) for cell cycle
analysis [28].
Cell Migration
Transwell (Boyden) chambers (Invitrogen, Carlsbad, CA), with a pore size of
8µm, were placed in triplicate into 12-well plates. Complete MCF10A media, which
served as a chemoattractant, was added to wells beneath the Transwell chamber. D283
cells (1×104) in low serum media were added to the Transwell chamber and the plates
were then incubated at 37˚C in a humidified 5% CO2 atmosphere for 24 hrs. The cells
were fixed with methanol for 10 mins and stained with 0.4% crystal violet for 2 hrs. Nonmigrated cells on the upper side of the filter were removed with a cotton swab, and the
filter was mounted on microscope glass slides. Slides were imaged using a dissection
microscope coupled to a digital microscope imager (Celestron).
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Western Blot
Total protein was isolated from cells in 6-well plates using RIPA (Cell Signaling).
Protein concentration was measured using a BCA kit (Pierce). 30–50 µg of protein were
separated on 12% to 15% Bis-Tris polyacrylamide gels (Bio-Rad) and then transferred to
PVDF membranes (Bio-Rad). Protein membranes were incubated in blocking buffer (1×
Tris-buffered saline, pH 7.5, 5% nonfat dried milk, 0.05% Tween 20) for 2 hours at room
temperature, followed by phospho-p53, p53, PTEN, phospho-Akt, Akt, phospho-Erk, or
Erk antibody (Cell Signaling), Fog2 antibody (Santa Cruz Biotechnology) or β-actin
antibody (Sigma-Aldrich) overnight at 4°C. The membranes were washed with 1× Trisbuffered saline containing 0.05% Tween 20, incubated with horseradish peroxidaselinked goat anti-mouse Ig (Santa Cruz) or goat anti-Rabbit Ig (Cell Signaling) for 1 hour
at room temperature, washed, and visualized with the SuperSignal West Dura
Chemiluminescent Substrate kit (PIERCE).
Mice
Athymic male nude (Foxn1nu/Foxn1nu) mice (5 weeks old) were purchased from
The Jackson Laboratory (Bar Harbor, ME) and maintained in the University of
Louisville’s AAALAC-accredited animal facility. All animal studies were conducted in
accordance with National Institutes of Health animal use guidelines, and a protocol
approved by the University of Louisville’s Institutional Animal Care and Use Committee.
Exponentially growing cells were harvested and injected subcutaneously (5.0x105
cells/animal) into nude mice (six per group). Each mouse was injected in each flank with
MCF10A cells stably over-expressing a Ras effector mutant alone in one flank, and
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MCF10A cells stably over-expressing the same Ras effector mutant in combination with
miR-200a in the other flank. Side of injection was randomized. Tumor size was
monitored once per week for 10 weeks before sacrificing. Tumors were harvested and
immediately formalin fixed. Tumors were embedded in paraffin, and tissue sections were
stained with hematoxylin and eosin.
Statistical Analysis
Colony formation data was analyzed by multivariate analysis of variance
(MANOVA) with T tests post hoc to look for individual effects with standard errors
corrected for multiple comparisons. Cell proliferation data were analyzed by linear
regression modeling with T tests post hoc to determine individual effects using standard
errors corrected for multiple comparisons. Cell Cycle Distribution was analyzed by
generalized linear models comparing G1 to combined S/G2 phases with binomial
response variables and parameters estimated by maximum likelihood. Log odds ratios
were further analyzed by T tests post hoc to evaluate individual effects using standard
errors corrected for multiple comparisons.
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Table 3. Statistical Analyses of colony formation in soft agar: miR-200a, oncogenes.
MCF10A cells stably overexpressing miR-200a alone or in combination with the
indicated
oncogenes.
MCF10A COLONY
FORMATION ASSAY - miR-200a + Oncogenes
Coefficients: (1 not defined because of
Estimat Error t value
(Intercept)
-1.023e-14 5.821e+00
miR200a
3.333e-01 8.233e+00
ras
6.400e+01 8.233e+00
cmyc
1.367e+01 8.233e+00
p53dd
2.300e+01 8.233e+00
ras:cmyc
-6.667e+01 1.164e+01
miR200a:ras
1.447e+02 1.164e+01
miR200a:cmyc
-1.300e+01 1.164e+01
miR200a:p53dd
-5.667e+00 1.164e+01

singularities)
Pr(>|t|)
0.000
1.000
0.040
0.968
7.774 3.68e-07
1.660
0.114
2.794
0.012
-5.726 1.98e-05
12.425 2.87e-10
-1.117
0.279
-0.487
0.632

***
*
***
***

Group 1

Group 2

colonies

t value

p value

vector

miR-200a

3.33E-01

4.05E-02

4.84E-01

vector

Ras

6.40E+01

7.77E+00

2.69E-07

vector

cMyc

1.37E+01

1.66E+00

5.76E-02

vector

p53dd

2.30E+01

2.79E+00

6.24E-03

**

vector

Ras + cMyc

1.10E+01

1.89E+00

3.80E-02

*

vector

miR-200a + Ras

1.45E+02

1.24E+01

2.93E-10

***

vector

-1.12E+00 8.60E-01

vector

miR-200a + cMyc -1.30E+01
miR-200a +
p53dd
-5.67E+00

miR-200a

miR-200a + Ras

2.09E+02

1.79E+01

8.86E-13

***

Ras

miR-200a + Ras

1.45E+02

1.25E+01

2.82E-10

***

Signif. codes:

-4.87E-01 6.84E-01

0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05
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Table 4 Statistical Analyses of colony formation in soft agar: miR-200a, Ras mutants.
MCF10A cells stably overexpressing miR-200a alone or in combination with the
indicated Ras effector mutants.
Colony formation - miR-200a + Ras Effector Mutants
Coefficients: (1 not defined because of singularities)
Estimate Std. Error t value Pr(>|t|)
(Intercept)
-1.641e-14 7.551e+00
0.000
1.0000
miR200a
2.333e+00 1.068e+01
0.218
0.8295
rase37g
5.667e+00 1.068e+01
0.531
0.6022
rast35s
2.333e+00 1.068e+01
0.218
0.8295
raswt
1.160e+02 1.068e+01 10.862 2.47e-09 ***
rasy40c
1.800e+01 1.068e+01
1.685
0.1092
miR200a:rase37g 4.333e+01 1.510e+01
2.869
0.0102 *
miR200a:rast35s 9.333e+00 1.510e+01
0.618
0.5443
miR200a:raswt
NA
NA
NA
NA
miR200a:rasy40c 2.333e+00 1.510e+01
0.154
0.8789

Group 1

Group 2

colonies

t value

vector

miR-200a

2.33E+00

2.18E-01

p
value
0.415

vector

E37G

5.67E+00

5.31E-01

0.301

vector

T35S

2.33E+00

2.18E-01

0.415

vector

Ras

1.16E+02

1.09E+01

0.000

vector

Y40C

1.80E+01

1.69E+00

0.055

vector

miR-200a + E37G 4.33E+01

2.87E+00

0.005

vector

miR-200a + T35S 9.33E+00

6.18E-01

0.272

vector

miR-200a + Y40C 2.33E+00

1.55E-01

0.440

miR-200a + miR-200a
4.90E+01
3.24E+00
E37G
miR-200a + E37G
4.57E+01
3.02E+00
E37G
miR-200a + miR-200a
1.17E+01
7.73E-01
T35S
miR-200a + T35S
1.17E+01
7.73E-01
T35S
Signif. codes: 0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05

0.002

**

0.004

**
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0.225
0.225

***

**

Table 5. Statistical Analysis of Cell Proliferation Data. MCF10A cells stably
overexpressing miR-200a alone or in combination with Ras.
Cell Proliferation Curve
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept)
0.116063
0.020842
5.569 1.54e-06 ***
time
0.070912
0.006865 10.330 3.19e-13 ***
time:miR200a
0.034543
0.008140
4.244 0.000115 ***
time:ras
0.065368
0.008140
8.031 4.29e-10 ***
time:miR200a:ras -0.056111
0.011511 -4.874 1.53e-05 ***
--Signif. codes: 0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1
Residual standard error: 0.08805 on 43 degrees of freedom
Multiple R-squared: 0.9309,
Adjusted R-squared: 0.9245
F-statistic: 144.9 on 4 and 43 DF, p-value: < 2.2e-16
Group 1

Group 2

Slope

t value

p value

vector
miR-200a
0.105455 3.052862 0.001939 ***
vector
Ras
0.13628
16.74201 0
***
vector
miR-200a + Ras 0.014801 1.285814 0.102695 ***
miR-200a +
miR-200a
0.009257 0.267985 0.394996
Ras
miR-200a +
Ras
-0.02157 -1.87369 0.96611
Ras
Signif. codes: 0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05

76

Table 6. Statistical Analyses of Cell Cycle Data. MCF10A cells stably
overexpressing miR-200a alone or in combination with the indicated oncogenes.
CELL CYCLE DATA
Coefficients: (1 not defined because of singularities)
Estimate Std. Error z value Pr(>|z|)
(Intercept)
0.98074
0.01762
55.66
<2e-16 ***
miR200a
-1.20118
0.02405 -49.94
<2e-16 ***
ras
-1.03059
0.02229 -46.23
<2e-16 ***
cmyc
-1.49792
0.02153 -69.56
<2e-16 ***
p53dd
-1.44509
0.02354 -61.40
<2e-16 ***
ras:cmyc
1.81266
0.02994
60.53
<2e-16 ***
miR200a:ras
1.29906
0.03249
39.99
<2e-16 ***
miR200a:cmyc
1.14627
0.03140
36.51
<2e-16 ***
miR200a:p53dd
0.79548
0.03300
24.10
<2e-16 ***
Group 1

Group 2

vector

miR-200a

log odds Fold Change z value
estimate
-0.22044 0.802165767 -9.1659

vector

Ras

-0.04985 0.95137212

vector

cMyc

-0.51718 0.596199462 -24.0214 0.00003

vector

p53dd

-0.46435 0.628543526 -19.726

vector

Ras + cMyc

2.7934

16.33646948 93.29993 0.99997

vector

miR-200a +
Ras
miR-200a +
cMyc
miR-200a +
p53dd
miR-200a

2.2798

9.774725269 70.16928 0.99997

2.12701

8.389743937 67.73917 0.99997

1.77622

5.907483872 53.82485 0.99997

0.26847

1.307961738 8.263158 0.99997

Ras

0.09788

1.102830438 3.012619 0.9987

vector
vector
miR-200a
+ Ras
miR-200a
+ Ras
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p value
0.00003

-2.23643 0.01266
0.00003

Results
miR-200a transforms immortalized rat epithelial cells
The RK3E cell line is an E1A-immortalized rat kidney epithelial cell line, whose
defining characteristic is monolayer growth under normal conditions, and foci formation
under transforming conditions such as Ras activation or Myc overexpression [181-183].
In order to determine the role of miRNAs in cell transformation, RK3E cells were
transiently transfected with individual miRNAs from our library of 366 miRNA genes
[180] and visually screened for foci formation (Figure 9A). A construct expressing cMyc was used as a positive control [154]. Negative vector control-expressing cells
formed no foci. Of the 366 miRNAs screened miR-141 and let-7e formed about the same
number of foci as c-MYC, and miR-200a formed more foci than c-Myc. These three
miRNAs were selected for an ensuing stringent cell transformation experiments. We
stably infected RK3E cells with lentivirus made from each of these three miRNAs or
vector control and assayed them for anchorage-independent growth in soft agar. All three
miRNAs induced colony formation in soft agar (Figure 9B).
In order to determine tumorigenicity of these miRNAs, RK3E cells stably
expressing each of these miRNAs were subcutaneously injected into nu/nu mice. Cells
expressing miR-141 or miR-200a formed orthotopic subcutaneous tumors (Figure 10),
but let-7e-expressing cells did not produce tumors (data not shown). miR-200a and miR141 are family members with identical seed sequences, thus miR-200a alone was
analyzed further.
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To determine potential mechanisms underlying this cell transformation, we
analyzed the expression of miR-200a target genes [102,184-186]. Consistent with the
literature, Western blot analyses showed that in RK3E cells expressing miR-200a, the
epithelial marker, E-cadherin, was up-regulated, and the mesenchymal marker, Vimentin,
was down-regulated compared to vector control (Figure 11A). Furthermore, expression
of the negative regulators of the PI3K/Akt pathway, Fog2 and Pten, was down-regulated,
concomitant with an increase in Akt phosphorylation (Figure 11B).
We next determined whether miR-200a acts as a driving force in cell
transformation. We employed the classical two-hit model of primary rodent cell
transformation by combining miR-200a with Ras, c-Myc, or p53dd in mouse embryonic
fibroblasts (MEFs). miR-200a overexpression in MEFs induces an initial increase in
proliferation; however, miR-200a expression alone, or in combination with either Ras or
c-MYC was unable to transform MEFs (data not shown). p53dd is known to immortalize
MEFs, however miR-200a was unable to cooperate with this tumor suppressor mutation
to transform these cells. Ras and Myc coexpression was able to transform primary MEFs.
Taken together, these results suggest that other genetic pathways active in RK3E cells,
but not in primary MEFs, are involved in miR-200a-mediated cell transformation and that
miR-200a is not a strong transforming component of the classical two-hit murine model.
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Figure 9. miR-200a transforms RK3E cells.

A

B

366 miRNAs

vector

let-7e

miR-200a

miR-141

Figure 9. miR-200a transforms RK3E cells. (A) Schematic of foci formation induced by transient
transfection of individual miRNA from our library of 366 miRNA minigenes. (B) Phase contrast
microscopy of 3-dimensional colonies formed in soft agar by RK3E cells stably overexpressing the
indicated miRNAs. Red arrowheads indicate colonies.
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Figure 10. miR-200a induces tumorigenesis of RK3E cells in
immunocompromised mice

miR-141

miR-200a

vector

Figure 10. miR-200a induces tumorigenesis of RK3E cells in
immunocompromised mice. Subcutaneous tumor formation of RK3E cells
overexpressing the indicated miRNAs
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Figure 11. miR-200a regulates EMT and stimulates Akt activity.
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B

vector miR-200a

vector

miR-200a

Figure 11. miR-200a regulates EMT and stimulates Akt activity.
(A) Western blot for the mesenchymal marker Vimentin and the epithelial marker, E. Cadherin in
RK3E cells lenti-virally infected with miR-200a or empty vector control. (B) Western blot for
members of the Akt activation pathway in RK3E cells.
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miR-200a augments Ras transformation of immortalized human mammary
epithelial cells.
In order to determine the role of the proliferative effects of miR-200a in human
cells, we chose the immortalized yet untransformed mammary epithelial cell line,
MCF10A, from a patient with fibrocystic disease [187]. This cell line is readily
transformed by overexpression of Ras or Myc, and normal morphology in threedimensional cell culture is disrupted by loss of p53 signaling [188-190]. Consistent with
our efforts to determine oncogenic cooperativity, we stably infected this cell line with
miR-200a alone, or in combination with Ras, c-MYC, or p53dd. The Ras construct
harbors a G12V mutation, rendering it constitutively active. p53dd is a truncated form of
the carboxy terminus of the p53 protein that binds wild type p53, resulting in a dominant
negative repression of p53 function [191]. To test for transformation, cells were assayed
for anchorage-independent growth in soft agar (Figure 12, 13). miR-200a alone did not
transform MCF10A cells. When miR-200a was expressed in combination with c-Myc or
p53dd, colony formation was not significantly increased compared with that of either
oncogene alone. However, colony formation increased more than three times in cells
expressing miR-200a in combination with Ras than that in cells expressing Ras alone
(Figure 13). Coexpression of Ras and c-Myc induced colony formation, but surprisingly,
their combined effects were not synergistic, that is, their combined effect did not show an
increase greater than the addition of both oncogene’s individual effects. MF10A cells
expressing miR-200a at 5-fold, 10-fold, and 15-fold increases above vector control were
transduced with empty vector or Ras, and assayed for colony formation. There was no
difference in the number of colonies formed in response to varying levels of miR-200a
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expression (Data not shown). Cells with a 10-fold increase in miR-200a expression were
used for subsequent experiments.
miR-200a synergizes with Ras to inhibit apoptosis.
We next analyzed these cells for changes in cell cycle progression (Figure 14, 15).
Compared to vector control, all experimental groups caused a decrease in G1 arrest.
Consistent with its effects on colony formation, Ras and Myc coexpression had the
smallest effect, decreasing G1 arrest from 70.93% to 55.52%. Compared to p53dd
alone, miR-200a in combination with p53dd caused the greatest increase in cell cycle
progression, decreasing G1 arrest from 38.48% to 28.88%. Surprisingly, G1 arrest was
unchanged between cells expressing Ras alone, and miR-200a in combination with Ras.
Furthermore, compared to miR-200a alone, G1 arrest in cells expressing miR-200a
combination with Ras increased from 43.83% to 50.15%. Compared to cMyc alone,
miR-200a with cMyc did not change G1 arrest levels. This indicates that induction of cell
cycle progression is not responsible for the combinatorial effect between Ras and miR200a on cell transformation. We next generated a cell proliferation curve in order to
compare growth rates of cells expressing miR-200a alone and cells expressing miR-200a
in combination with Ras (Figure 16). miR-200a alone and in combination with Ras
significantly increased proliferation compared to vector control; however, miR-200a
combined with Ras did not significantly increase proliferation compared to miR-200a
alone. Ras alone showed the greatest increase in proliferating cells. This indicates that
stimulation of proliferation is not responsible for the interactive effect between Ras and
miR-200a, and that Ras is unable to enhance the proliferative function of miR-200a.
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We next examined these cells for changes in migratory ability, a cancer hallmark,
and a phenotype frequently regulated by miR-200a and its family members. miR-200a
decreased trans-well cell migration of MCF10A cells compared to vector control (Figure
17). Ras alone greatly increased cell migration above vector control. Cells expressing
Ras in combination with miR-200a also showed decreased migration compared to Ras
alone; however, these cells formed dense, three-dimensional colonies before and after
migrating. Inhibition of cell migration is consistent with the literature and miR-200a’s
established function in regulation of EMT [124,186].
When seeded in Matrigel extracellular matrix, MCF10A cells grow to form
polarized acinar structures with a distinct hollow lumen, which resembles normal breast
tissue development [190]. To gain insight into the potential effects of the cooperation of
miR-200a with Ras on cell growth and morphology in the context of acinar structure
formation, we seeded cells in Matrigel, and analyzed three dimensional acinus formation
by confocal microscopy (Figure 18). Acini were examined for changes in three
characteristics: morphology, E-Cadherin expression, and cleaved Caspase-3 expression.
Acini were stained for E-Cadherin to facilitate inspection of morphological and structural
changes, as well as changes in E-Cadherin expression and subcellular localization (Figure
19). Vector control cells formed regular spherical structures with hollow lumen. Cells
expressing miR-200a alone formed regular spherical structures, with and without regular
lumen clearance. Cells expressing Ras alone formed very irregular and lobular three
dimensional structures with loosely packed cells and partial lumen clearance. Cells
expressing miR-200a in combination with Ras formed densely packed, slightly irregular
spherical structures with no lumen clearance. Notably, in acini expressing Ras alone, or
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Ras with miR-200a, E-cadherin was localized diffusely in the cytoplasm, rather than at
the plasma membrane. This is consistent with studies showing disruption of normal
adherens junctions in transformed cells, and sequestering of E-Cadherin away from the
plasma membrane in the cytoplasm [192,193]. In order to determine whether the cause
of the loss of lumen clearance in response to miR-200a expression was loss of apoptosis,
we examined levels of cleaved Caspase-3 in matrigel-seeded cells allowed to grow as
acini for 3 days (Figure 18). Acini containing vector or miR-200a expressed high levels
of cleaved Caspase-3 and showed normal lumen clearance. This is in contrast to the loss
of lumen clearance in acini expressing miR-200a after seven days (data not shown).
Acini expressing Ras alone formed lobular structures at 3 days, and expressed lower
levels of cleaved Caspase-3. Acini structures expressing Ras in combination with miR200a showed tightly packed structures with no lumen clearance, and little to no cleaved
Caspase-3. Taken together, these results indicate that miR-200a alone decreases lumen
clearance by increasing proliferation without decreasing apoptosis (Figures 16 and 19);
however, miR-200a synergizes with Ras to inhibit apoptosis as evidenced by the dramatic
reduction of cleaved Caspase-3 (Figure 19).
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Figure 12. miR-200a augments Ras-induced malignant cellular transformation.

miR-200a

Ras

c-Myc

p53dd

vector

Figure 12. miR-200a augments Ras-induced malignant cellular transformation.
Soft agar colony formation: bright field microscopy of MCF10A cells stably infected with the
indicated oncogenes alone (left panels) or in combination with miR-200a (right panels).
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Figure 13. miR-200a augments Ras-induced malignant cellular transformationquantification.
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Figure 13. miR-200a augments Ras-induced malignant cellular transformation.
Quantification of soft agar colony formation in Figure 12; 2000 MCF10A cells stably
infected with miR-200a and the indicated oncogenes were plated in triplicate. The
data represents means of three independent experiments +/- standard error.
* p ≤ 0.05 compared to vector control, † p ≤ 0.05 compared to miR-200a,
¥ p ≤ 0.05 compared to Ras.
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Figure 14. miR-200a increases cell cycle progression, but not in combination with
oncogenes.
Vector
Freq. G1 = 70.93
Freq. S = 10.07
Freq. G2 = 16.51

miR-200a
Freq. G1 = 43.83
Freq. S = 28.55
Freq. G2 = 26.09

Ras
Freq. G1 = 47.70
Freq. S = 26.94
Freq. G2 = 23.35

miR-200a + Ras
Freq. G1 = 50.15
Freq. S = 16.98
Freq. G2 = 27.23

cMyc
Freq. G1 = 37.07
Freq. S = 34.96
Freq. G2 = 27.23

miR-200a + cMyc
Freq. G1 = 35.48
Freq. S = 35.07
Freq. G2 = 27.73

p53dd
Freq. G1 = 38.48
Freq. S = 32.94
Freq. G2 = 26.86

Ras + cMyc
Freq. G1 = 55.52
Freq. S = 24.59
Freq. G2 = 17.56

miR-200a + p53dd
Freq. G1 = 28.88
Freq. S = 46.43
Freq. G2 = 22.69

Figure 14. miR-200a increases cell cycle progression, but not in combination with oncogenes.
Representative histograms of cell cycle distributions of MCF10A cells infected with the indicated
oncogenes alone or in combination with miR-200a.
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Figure 15. miR-200a increases cell cycle progression alone, not synergistically
with oncogenes.
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Figure 15. miR-200a increases cell cycle progression alone, not synergistically
with Ras. Quantification of cell cycle distribution in Figure 6; MCF10A cells infected
with the indicated oncogenes alone or in combination with miR-200a.
* p ≤ 0.05 compared to vector control, † p ≤ 0.05 compared to miR-200a,
¥ p ≤ 0.05 compared to Ras. P-values calculated for cell cycle progression out of G1
phase.
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Figure 16. miR-200a mediated increase in proliferation is not enhanced by Ras.
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Figure 16. miR-200a mediated increase in proliferation is not enhanced by Ras.
Cell proliferation curve of MCF10A cells infected with miR-200a, Ras, or miR-200a
in combination with Ras. Cell proliferation assayed by MTT assay. Cells were plated
in triplicate; data are means of three independent experiments +/- standard error.
* p ≤ 0.05 compared to vector control, † p ≤ 0.05 compared to miR-200a,
¥ p ≤ 0.05 compared to Ras.
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Figure 17. miR-200a inhibits cell migration.

.
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miR-200a

Ras
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Figure 17. miR-200a inhibits cell migration. Transwell cell migration of MCF10A
cells infected with miR-200a, Ras, or miR-200a in combination with Ras and stained
with crystal violet.

92

Figure 18. MCF10A cells form hollow acini in Matrigel 3 dimensional culture.

Dapi
E-Cadherin
Figure 18. MCF10A cells form hollow acini in Matrigel 3 dimensional culture.
Upper left: Schematic of three dimensional acinus formed by MCF10A cells in
Matrigel. Black line indicates equatorial confocal plane of focus. Upper right:
Schematic of hollow lumen visualized by confocal microscopy focused at center line
depicted in left diagram. Lower: representative image of acinar structures formed
after 14 days in Matrigel by MCF10A stably infected with vector control.
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Figure 19. miR-200a cooperates with Ras to inhibit apoptosis.
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Figure 19. miR-200a cooperates with Ras to inhibit apoptosis. Three dimensional
acinar formation after 5 days in Matrigel; MCF10A cells infected as indicated, stained
for E-Cadherin (green, left panels) and cleaved Caspase-3 (red, right panels).
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miR-200a cooperates with the RalGEF Ras effector pathway
Ras activity results in the activation of a wide array of downstream signaling
pathways; however, the three main effectors that are activated by Ras are Raf, PI3K, and
RalGEF [29]. We made use of three Ras mutants to determine the mechanism behind
miR-200a cooperating with Ras to increase MCF10A cell transformation. The T35S
point mutation allows for activation of only the Raf-Erk effector pathway; the Y40C
point mutation allows for activation of only the PI3K effector pathway, and the E37G
point mutation allows for activation of only the RalGEF effector pathway (Figure 20).
We expressed miR-200a along with each of these individual effector pathway mutations
to determine which pathway miR-200a specifically cooperates with and assayed them for
anchorage-independent growth in soft agar (Figure 21, 22). Compared to T35S alone,
miR-200a in combination with T35S caused a small, but insignificant increase in colony
formation. miR-200a in combination with Y40C did not cause an increase in colony
formation compared to Y40C alone. miR-200a caused a significant ten-fold increase in
cells expressing both E37G and miR-200a compared to cells expressing E37G alone.
Notably, un-mutated Ras formed more colonies than any of the effector mutants alone or
combined with miR-200a, indicating that while miR-200a synergizes with the E37G
mutant to enhance cell transformation, these two hits do not completely recapitulate the
full effect of Ras.
We next analyzed MCF10A cells expressing Ras effector mutants alone or in
combination with miR-200a for changes in cell cycle progression (Figure 23). T35S
significantly decreased G1 phase arrest, but when miR-200a was added, the effect was
ablated. Y40C alone, or in combination with miR-200a did not show any change in cell
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cycle progression, consistent with the lack of effect on colony formation. E37G alone
induced a modest but significant increase in G1 phase arrest. However, E37G in
combination with miR-200a significantly decreased G1 phase arrest, compared to both
vector control and E37G alone, indicating that miR-200a induction of cell cycle
progression contributes to its cooperation with RalGEF signaling in cell transformation.
We next analyzed the three dimensional growth in Matrigel of MCF10A cells
expressing E37G or T35S Ras effector mutants alone and in combination with miR-200a
to determine changes in structure and apoptosis (Figure 24). Cells expressing E37G Ras
mutant alone formed regular, round acini with hollow lumen, but had lower levels of
cleaved Caspase-3 than the vector control (Figure 19,24). When miR-200a was added,
cells expressing E37G Ras mutant formed large, irregularly shaped structures with tightly
packed cells and diffuse E-Cadherin staining; punctate cleaved Caspase-3 was visible
throughout the structures, along with apoptotic cells; however, no lumen clearance was
observed, similar to Ras alone. Cells expressing T35S Ras mutant alone formed regular
spherical acini with strong plasma membrane localization of E-Cadherin; cleaved
Caspase-3 staining showed uncompromised apoptosis levels in these acinar structures,
however, no lumen clearance was observed, possibly due to slower growth. Cells
expressing T35S in combination with miR-200a formed irregular acinar structures, most
without lumen clearance; structures that did exhibit lumen clearance were part of larger,
lobular structures, indicating irregular growth despite lumen clearance; plasma membrane
localization of E-Cadherin was retained, and structures showed low levels of cleaved
Caspase-3 staining.
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These results indicate that miR-200a cooperates with E37G mutant to disrupt
acinar growth; however, the change in acinar structure is likely due to increased
proliferation rather than a change in apoptosis compared to E37G alone. These effects
were not seen when miR-200a was added to T35S, demonstrating that miR-200a does not
cooperate with or enhance the effects of Raf signaling on acinar morphology. Taken
together, this strongly implicates physiological significance for the interaction between
miR-200a and E37G.

98

Figure 20. Ras effector pathways.
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Figure 20. Ras effector pathways. Schematic of the 3 main effector pathways of

Ras. Indicated on the leftmost arrows are the activating point mutations that allow for
activation of only that pathway.
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Figure 21. miR-200a cooperates with the RalGEF pathway to increase cell
transformation.
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Figure 21. miR-200a cooperates with the RalGEF pathway to increase cell
transformation. Soft agar colony formation assay of MCF10A cells stably infected
with the indicated Ras effector mutants alone (left panels) or in combination with
miR-200a (right panels) compared to constitutively activated Ras (bottom left panel).
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Figure 22. miR-200a cooperates with RalGEF pathway activation.
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Figure 22. miR-200a cooperates with RalGEF pathway activation. Quantification
of soft agar colony formation in Figure 13; MCF10A cells stably infected with miR200a alone or in combination with the indicated Ras effector pathway mutants. Cells
were plated in triplicate. Data represent means of three independent experiments +/standard error.
* p ≤ 0.05 compared to vector control, † p ≤ 0.05 compared to miR-200a,
€ p ≤ 0.05 compared to E37G.
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Figure 23. miR-200a cooperates with the RalGEF pathway to induce cell cycle
progression.
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Figure 23. miR-200a cooperates with the RalGEF pathway to induce cell cycle
progression. Cell cycle distribution analyzed by flow cytometry; MCF10A cells
infected with the indicated oncogenes alone or in combination with miR-200a.
* p ≤ 0.05 compared to vector control, € compared to E37G. P-values calculated for
cell cycle progression out of G1 phase.
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Figure 24. miR-200a cooperates with RalGEF signaling to disrupt acinar growth.
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Figure 24. miR-200a cooperates with RalGEF signaling to inhibit apoptosis and
induce proliferation. Three dimensional acinar formation after five days in Matrigel;
MCF10A cells infected as indicated, stained for E-Cadherin (green, left panels) and
cleaved Caspase-3 (red, right panels).
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miR-200a stimulates Akt and suppresses p53.
To further elucidate the mechanism of miR-200a in malignant cell transformation,
we analyzed MCF10A cells either transiently (Figure 25A) or stably (Figure 25B) overexpressing miR-200a for known targets as well as potential downstream effectors.
Similar to RK3E cells, Fog2 expression is decreased in MCF10A cells expressing miR200a, accompanied by an increase in Akt phosphorylation. However, the miR-200a
target Pten is not down-regulated in MCF10A cells. We also analyzed p53 levels in
unchallenged and Doxorubicin-challenged MCF10A cells to determine the effect of miR200a in the apoptotic response. In unchallenged cells, basal levels of p53 were
unchanged between vector control and miR-200a expressing cells. In response to
Doxorubicin, p53 protein expression and phosphorylation increased in vector control
cells, but not in cells expressing miR-200a. Because of the involvement of miR-200a in
the Akt pathway and its cooperation with the RalGEF pathway, we also analyzed protein
expression and phosphorylation levels of Erk, the third Ras effector pathway. In cells
transiently expressing miR-200a, Erk expression and phosphorylation levels decreased
compared to vector control; however, in cells stably expressing miR-200a, expression
and phosphorylation levels of Erk were unchanged, indicating that miR-200a does not
affect the Raf effector pathway of Ras.
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Figure 25. miR-200a stimulates Akt signaling and inhibits p53.
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Figure 25. miR-200a stimulates Akt signaling and inhibits p53. (A) Western Blot
of MCF10A cells transiently transfected with miR-200a. (B) Western Blot of
MCF10A cells stably infected with miR-200a.
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miR-200a synergizes with the RalGEF signaling pathway to induce tumorigenesis.
We subcutaneously injected immunocompromised nude mice with MCF10A cells
expressing miR-200a in combination with the T35S mutant, or with the E37G mutant and
histologically analyzed resulting tumors [194]. MFC10A cells expressing miR-200a in
combination with the E37G mutant were the only cells that formed subcutaneous tumors
(Figure 26).

Transformed MCF10A cells recapitulate human proliferative mammary

disease in subcutaneous tumors in nude mice [188]; thus we stained tumor sections with
H&E and histologically examined them for abnormal tissue structures (Figure 27). All
tumors were vascularized, regardless of size (Figure 27A), and duct formation was either
absent (Figure 27C) or severely abnormal (Figure 27B). Defined structures of dense
connective tissue were present with intermittent sections of loose connective tissue that
infrequently contained small structures resembling ducts, but without regular epithelial
lining (Figure 27B). The highly irregular tissue structure and loss of normal duct
formation resembles the histology seen in invasive carcinoma of human mammary
proliferative disease. The severity of tissue architecture disruption indicates the strong
potential of the interaction between miR-200a and the RalGEF pathway to contribute to
cancer initiation and tumorigenesis.
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Figure 26. miR-200a cooperates with the RalGEF pathway to induce
tumorigenesis in immunocompromised mice.
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Figure 26. miR-200a cooperates with the RalGEF pathway to induce
tumorigenesis in immunocompromised mice. (A) Average tumor size after 10
weeks in nude mice subcutaneously injected with the indicated Ras effector pathway
mutants alone or in combination with miR-200a. (B) Representative images of tumor
formation. Each mouse was injected in each flank with MCF10A cells stably overexpressing a Ras effector mutant alone in one flank, and MCF10A cells stably overexpressing the same Ras effector mutant in combination with miR-200a in the other
flank. N=6 for each group.
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Figure 27. miR-200a cooperates with the RalGEF pathway to induce tumor
pathology resembling invasive human proliferative breast disease.
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Figure 27. miR-200a cooperates with the RalGEF pathway to induce tumor
pathology resembling invasive human proliferative breast disease.
A, B, C. Representative H&E staining of tumors formed by E37G+miR-200a
MCF10A cells. Tissue structures resembling human mammary histology are labeled
as follows: B: blood vessel, L: Loose connective Tissue, D: Dense connective tissue,
Dt: Duct.

111

Discussion
miR-200a and EMT
miR-200a was originally studied as a tumor suppressor and inhibitor of migration
and metastasis because of its inhibition of EMT. We verified that this new oncogenic
role of miR-200a occurs alongside upregulation of epithelial markers. Consistent with
this, cells overexpressing miR-200a alone or in combination with Ras showed decreased
migration compared to vector control or Ras alone, respectively. In nude mice, miR-200a
synergizes with the RalGEF pathway to form subcutaneous tumors with histology that
resembles invasive proliferative breast disease. This is especially notable because miR200a has been reported to be a crucial player in the maintenance of epithelial cell
polarity, particularly in the mammary gland [195]. The disruption of tissue structure by
the combination of miR-200a over-expression with RalGEF signaling highlights the
significance of this interactive effect.
miR-200a, Fog2 and Proliferation
Only recently has the oncogenic role of miR-200a in proliferation been studied. It
directly targets Fog2 and positively regulates cell growth [102]. Following this, more
evidence has revealed the important role of the miR-200 family and Fog2 in regulating
PI3K activity in the context of insulin signaling, indicating the significance of the miR200a/Fog2/PI3K axis in human health [196-199]. We have demonstrated that miR-200a
transforms immortalized rat RK3E kidney epithelial cells and augments Ras
transformation of immortalized human MCF10A cells. This is consistent with a study by
Zhao et al. demonstrating that activated PI3K complements Ras activation in
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transformation of human mammary epithelial cells (HMECs) [200]. Our study shows
that miR-200a overexpression decreases Fog2 expression and increases Akt
phosphorylation as Fog2 is a negative regulator of PI3K activity. Notably, PI3K/Akt
signaling is one of the three main Ras-effector pathways, and we show that miR-200a
augments Ras transformation of MCF10A cells. More specifically, miR-200a
complements the RalGEF/Jnk pathway to enhance colony formation in soft agar.
miR-200a alone significantly increased cell proliferation and cell cycle
progression. Yet miR-200a in combination with Ras did not significantly increase cell
proliferation or cell cycle progression out of G1 above that seen in cells overexpressing
miR-200a alone. Indeed, miR-200a in combination with Ras had a negative interaction
effect on cell proliferation compared to Ras alone. This indicates that stimulation of the
pro-proliferative PI3K/Akt pathway is not responsible for the synergistic effect between
Ras and miR-200a, indicating that Ras activates PI3K/Akt signaling to high levels that
can not be further enhanced by miR-200a suppression of Fog2. Conversely, miR-200a in
combination with RalGEF signaling causes a significant decrease in G1 cell cycle arrest
compared to RalGEF alone, indicating that miR-200a induction of cell cycle progression,
rather than inhibition of apoptosis, is important for cooperation with RalGEF signaling.
It is crucial to note that the phenotypic response to miR-200a overexpression in
the context of Ras signaling may be cell- or tissue-type specific. miR-200a has a wellstudied dichotomous role in cancer, and both its overexpression and down-regulation
have been associated with increased tumorgenesis [105,119]. These studies
demonstrating miR-200a’s contradictory functions emphasize the potential for tissuespecific signaling and pathway interactions.
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miR-200a, p53, and Inhibition of Apoptosis
Supporting the synergy between Ras and miR-200a are the changes in acinar
structure and intra-luminal apoptosis. miR-200a alone did not decrease cleaved Caspase3 levels in the lumen of acini. Although lumen formation was curtailed when Ras was
expressed alone, cleaved Caspase-3 staining was not ablated, indicating that an increase
in proliferation, rather than loss of apoptosis was responsible for the lack of lumen
clearance in MCF10A-Ras acini. However, when Ras and miR-200a were expressed
together, cleaved Caspase-3 levels decreased dramatically, indicating that miR-200a
synergizes with Ras to elicit inhibition of apoptosis. Loss of apoptosis is mechanistically
supported by western blot analyses showing down-regulation of p53 protein and
phosphorylation levels by miR-200a in MCF10A cells. miR-200a is known to directly
target p53 and inhibit apoptosis [53], and expression of p53dd in MCF10A cells has been
shown to inhibit apoptosis and cause an EMT-driven loss of normal acini formation
including normal structure and lumen clearance [190]. However, miR-200a is a strong
inhibitor of EMT, indicating that miR-200a disruption of p53 leading to reduced
apoptosis is the dominant force in disrupting normal lumen clearance, not EMT.
miR-200a Cooperates with RalGEF
The Raf-Erk effector pathway is considered largely responsible for Rasmediated transformation of murine cells [201,202]; however, differences exist between
the transformation of human cells and rodent cells. The RalGEF effector pathway alone is
able to recapitulate approximately 60% of Ras-induced transformation of human
embryonic kidney cells, but was not able to induce tumorigenesis in vivo [203].
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Consistent with this, our study shows that expression of the E37G mutant (activating the
RalGEF effector pathway) alone in MCF10A cells was not able to induce tumorigenesis.
However, we show that the combination of miR-200a over-expression and RalGEF
pathway activation is enough to induce malignant cell transformation and subcutaneous
tumor formation in vivo. This effect is not seen when miR-200a overexpression is
combined with either mutants activating the PI3K pathway (Y40C mutant) or the Raf/Erk
pathway (T35S mutant). miR-200a overexpression alone was insufficient to induce
colony formation or tumorigenesis, indicating that the combination of Akt activation and
loss of p53 is not enough to effect transformation. By cooperating with the RalGEF
pathway to transform cells, miR-200a demonstrates that loss of p53 syngergizes with
gain of Akt and RalGEF signaling to transform MCF10A cells. This is consistent with a
study showing transformation of human embryonic kidney cells by the cooperation of
PI3K and RalGEF signaling with loss of p53 in a setting of Rb loss and telomerase gain
of function [18]. Rangarajan et al. also reaffirm the importance of RalGEF signaling in
human cell transformation compared to mouse cell transformation relying more heavily
on the Raf effector pathway [18].

Overall, this shows that suppression of p53 and

stimulation of Akt by miR-200a is enough to transform immortalized Rat cells, but not
immortalized human cells; however, the addition of RalGEF signaling enables miR-200a
to transform immortalized human MCF10A cells and induce tumorigenesis.
In summary, our results show that miR-200a enhances Ras-mediated
transformation of human cells. This is the first study that delineates miR-200a’s function
in malignant cell transformation. We also show that miR-200a synergizes with the
RalGEF-activating E37G Ras effector mutant to transform MCF10A cells and induce
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tumorigenesis in vivo, providing mechanistic insight into the mechanism of action of this
dichotomous miRNA. By determining that cooperation with RalGEF is necessary for
miR-200a-mediated cell transformation, we have illuminated a new, specific role for
miR-200a in malignancy. Furthermore, we anticipate that future studies examining the
concomitant genetic changes occurring during malignant transformation will thoroughly
reveal the role of miR-200a in cancer initiation and bespeak its prognostic potential.
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CHAPTER IV
CONCLUSIONS AND FUTURE DIRECTIONS
Conclusions
Cancer is a deadly disease that claims the lives of over half a million people every
year in the United States. Cancer is a progressive disease that begins with malignant cell
transformation and culminates in metastasis. It is critical to understand cancer initiation
to aid in cancer prevention, and to develop methods to detect and diagnose early stages of
cancer before deadly metastasis develops.
In this study, we employed a biphasic approach to determine miRNA involvement
in malignant cell transformation. The first step involved profiling our library of 366
miRNAs to determine the role of miRNA clusters in four major cancer signaling
pathways. In this screen, we were able to provide a panoramic view of the effects of
miRNAs on AP-1, NF-κB, p53, and c-Myc signaling. In our miRNA cluster profiling
study, we found that 200b~429, which includes miR-200a, down-regulates p53 activity.
miR-200a was demonstrated to directly target p53, reduce protein levels, and inhibit
apoptosis. These results provide a strong foundation for the study of miR-200a as an
oncomiR. miRNA clusters frequently function via cooperative targeting that involves
cluster members suppressing different effectors of the same signaling pathway, or
multiple subunits of a protein complex in order to produce a larger regulatory effect.
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Given miR-200a’s role in p53 suppression, it is likely that the entire 200b~429 cluster, as
well as its family cluster 200c~141, plays a role in regulating apoptosis.
The second phase of this study was an epithelial cell screening assay to determine
the ability of miRNAs to transform epithelial cells. The immortalized RK3E cell line in
particular was employed because of its growth as a monolayer that becomes three
dimensional foci formation upon transformation with an oncogene. From this assay, we
found that miR-200a transforms RK3E cells. We further characterized the transformative
potential of miR-200a in the untransformed, immortalized human MCF10A cell line. We
found that miR-200a enhances Ras-mediated transformation of this cell line. These
results are consistent with a study that shows that knockdown of the high endogenous
miR-200a levels in MCF7 breast cancer cells reduces soft agar colony formation [62].
Mechanistic studies showed that miR-200a suppresses p53 protein levels and
phosphorylation, as well as Fog2 protein levels. Fog2 is a direct target of miR-200a and
a negative regulator of PI3K activity. miR-200a overexpression increased proliferation
and cell cycle progression, but when Ras was added, we did not see a combinatorial
effect. This indicates that the anti-apoptotic signaling mediated by miR-200a suppression
of p53 is responsible for enhancing Ras-induced transformation. This enhancement of
Ras-mediated cell transformation implicates a potential role for miR-200a in Ras-driven
malignancies, for example pancreatic cancer. Further characterization of the mechasnism
of action of miR-200a showed that miR-200a cooperates with the RalGEF effector
pathway of Ras to induce soft agar colony formation and tumorigenesis in
immunocompromised mice. Inability of miR-200a to transform immortalized human
MCF10A cells indicates that miR-200a stimulation of Akt activity and suppression of
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p53 is not enough to transform MCF10A cells; however, the addition of RalGEF
signaling in this setting induces transformation. These results demonstrate a role for
miR-200a in malignant cell transformation and provide a specific cellular context where
miR-200a acts as an oncomiR rather than a tumor suppressor.
In summary, this work reveals a new role for miR-200a in malignancy. We show
that miR-200a transforms immortalized rat RK3E cells, and when over-expressed with
Ras, it transforms immortalized human MCF10A cells. Taken together, these results
indicate that miR-200a is pro-oncogenic. We also show that miR-200a transforms
MCF10A cells by cooperating with RalGEF pathway activation, but not activation of the
PI3K/Akt or Raf/Erk pathways, which are the other two main effectors of Ras. This
transformative ability underscores the importance of miR-200a in the Akt and p53
pathways. Our results highlight the importance of the specific cellular environment when
characterizing the function of miR-200a. In particular, it is crucial to evaluate miR-200a
expression within the setting of concomitant genetic changes occurring during malignant
transformation.
Future Directions
miR-200 family
This study focuses on the transforming ability of a single miRNA, miR-200a,
which exists both as a member of a miRNA cluster, as well as a member of a fivemembered miRNA family. Future studies focusing on the individual effects of miR-200
family members will provide insight into the function of this family, and studies in which
the miR-200 family is expressed at disease-relevant levels or ratios will provide an
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understanding of the dysregulation of this entire family, as well as its individual
members, within the context of cell transformation.
Noncoding RNAs
The field of noncoding RNAs is rapidly expanding to encompass lncRNAs,
piRNAs, ceRNAs…the list continues ad nauseam. These novel regulators provide
insight into the control of miRNA-based gene silencing. For example, ceRNAs, or
competing endogenous RNAs, are highly abundant mRNAs that act as miRNA sponges,
titrating potent miRNAs out of the pool of gene regulators, thereby unsilencing miRNA
targets while the ceRNAs themselves experience insignificant downregulation by these
targeted miRNAs. The presence of ceRNAs provides another level of cell context in
which miR-200a is functioning.
Global gene expression effects
MicroRNA studies initially began as a race to discover as many new direct
miRNA targets as possible without follow-up experiments to determine physiological
relevance. As studies have progressed, it has become clear that miRNA effects are likely
not due to targeting one single gene, as miRNAs have the potential to 1) target multiple
genes at once and 2) be regulated by their own targeting mechanism e.g. by ceRNAs.
Thus it is crucial to view the “one target per miRNA” perspective with caution, and
future studies should take a more global approach to profile changes in gene expression
in response to changes in miRNA levels. This study identifies p53 and Fog2 as key
targets of miR-200a in the context of cell transformation; however, it is highly probable
that miR-200a targets a plethora of genes to regulate multiple signaling pathways. This
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view is further complicated by the need to characterize the combined effects of the entire
miR-200 family.
Clinical Relevance
Because of the dichotomous role of miR-200a in cancer initiation, progression,
and metastasis, it has the potential to serve as a context-specific biomarker for staging
cancer diagnoses or providing prognostic information. For example, early stage
carcinomas overexpressing miR-200a alone may be less aggressive than tumors
overexpressing miR-200a in the setting of constitutive Ras activation, or increased
RalGEF signaling.
In particular, changes in expression—both elevations and decreases—of miR200a are frequently implicated in breast cancer, providing an array of evidence for the
contradictory role of mir-200a in cancer. Future studies focused on miR-200a expression
in breast cancer tumor samples stratified into cohorts based on prognosis, survival, and
estrogen and progesterone receptor status will provide significant insight into the specific
contexts in which miR-200a inhibits or contributes to cancer initiation and progression.
Understanding the prognostic potential of this miRNA, and by extension the entire miR200 family, would provide clinicians with the tools to better diagnose and treat cancer
based on the personalized molecular profiles of patients.
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